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The concept of crystal engineering is making crystals with a purpose and it is an 
indisputable fact that multicomponent molecular solids such as co-crystals, metal-
organic frameworks (MOFs), and solid solutions are at the forefront of crystal 
engineering research. Multicomponent crystalline systems are important targets 
in the quest for novel solid forms that can show improvement of physical and 
chemical properties (solubility, intrinsic dissolution rate, morphology, thermal and 
hydration stability, etc.) compared to those of the parent components. As a 
result, multicomponent solids can find application in a variety of industrial fields. 
The research activity performed in my PhD was mainly dedicated to the 
investigations of multicomponent crystalline assemblies, namely molecular and 
ionic co-crystals and molecular solid solutions. The project can be subdivided into 
the following topics: 
1. Investigation of solid solutions consisting of organic molecules. 
2. Co-crystallization as a tool to modify physicochemical properties of interest. 
3. The effect of co-crystallization on chirality and its possible application for 
chiral resolution. 
The first two parts of the project were focused on the search for novel 
multicomponent crystalline assemblies capable of modifying the physicochemical 
properties of interest: thermostability for the obtained molecular solid solutions 
and enhancement of the solubility and intrinsic dissolution rate characteristics for 
the ionic co-crystals. The final chapter of this project was dedicated to the 
investigation of the influence of co-crystallization of chiral molecules of 
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1. CHAPTER I - INTRODUCTION 
 
1.1. Crystal engineering 
Crystal engineering has been defined by Desiraju in 1989 as “the understanding of 
intermolecular interactions in the context of crystal packing and in the utilisation 
of such understanding in the design of new solids with desired physical and 
chemical properties”.1 Substantially, crystal engineering is a powerful tool to gain 
control on the arrangement of the molecules/ions in the solid state via non-
covalent interactions such as hydrogen and halogen bonding, as well as ionic, van 
der Waals and π-interactions.2 Obviously, the solid-state packing arrangement of 
the building blocks (molecular and/or ionic) can dramatically affect the materials 
properties. Thus, the scientists in the field of crystal engineering aim at the 
development of the solids with the desired properties using the knowledge of the 
properties of their components. This rather challenging goal can be achieved via 
understanding and/or prediction of the spatial distribution and intermolecular 
interactions of the components in the solid.  
Apparently, most materials that find some practical application are crystalline 
solids. Crystals per se are supramolecular entities composed of molecular and/or 
ionic building blocks. According to Dunitz: “A crystal is, in a sense, the 
supramolecule par excellence: a lump of matter, of macroscopic dimensions, 
millions of molecules long, held together in a periodic arrangement by just the 
same kind of interactions as are responsible for molecular recognition and 
complexation at all levels - ion-ion, ion-dipole, dipole-dipole interactions, 
hydrogen bonding, London forces, and so on”.3 This defines a crystal as a 
“supramolecule”- an assembly of molecules via mutual recognition. The molecules 
are composed of atoms connected via covalent bonds, whereas the 
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molecules/ions making up such a “supramolecule” are held together via 
intermolecular interactions.4 Consequently, “making crystals by design”5 has 
become the paradigm of crystal engineering. Crystal engineering, as such, can be 
considered as a subject at the intersection of materials science and 
supramolecular chemistry.5 Supramolecular chemistry has been defined as a 
science “beyond the chemistry of the molecule” or as “the chemistry of the 
intermolecular bond”.6 
In fact, the process of crystal making essentially resembles the classical chemical 
experiments for the development of a new molecule: the modelling of a 
molecule, development of the most appropriate synthetic route, characterization 
of the obtained products, assessment of its properties.5 The crystal making 
process also requires the existence of a project – a goal for the formulation of 
new crystalline materials, the elaboration of a suitable design strategy, 
characterization of the obtained materials and the evaluation of its 
performance.5, 7 In addition, in organic synthesis a retrosynthetic approach is 
employed to develop a synthetic strategy.8 The idea of this approach is to simplify 
the molecular structure into basic units – synthons 8, 9 that could be used as a 
synthetic tool in the synthesis of complex organic molecules. In the crystal making 
process, in turn, “supramolecular synthons” are typically involved. Desiraju 
defined supramolecular synthons as “structural units within supermolecules which 
can be formed and/or assembled by known or conceivable synthetic operations 
involving intermolecular interactions”.4 Put it differently, supramolecular synthons 
are spatial arrangements of intermolecular interactions and the main goal of 
crystal engineering is to recognize and to use them wisely in the design of 
materials.10 Scheme 1.1-1 represents several examples of supramolecular 
synthons formed via hydrogen bonding.4, 11, 12 Synthons 1-3 are homosynthons 
exhibited by carboxylic acid (1 and 2) and amide dimers (3), correspondingly. 
Synthons 1 and 2 show the possibility of different arrangements of the same 
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chemical group. Synthon 4-6 are examples of heterosynthons. Synthon 1-6 have 
strong C=OH–O; N–HO; and O–HN interactions. Synthons 7-9 are less 
favoured synthon with either one weak C–HO=C and one strong O–HN (8) or 
both weak C–HO=C hydrogen bonds (7 and 9). 
 
 
Scheme 1.1-1 Supramolecular synthons formed via hydrogen bonds. 
 
Hydrogen bonding the most frequently occurring noncovalent interaction in 
recognition processes.13 Etter has defined hydrogen bond as “an interaction that 
directs the association of a covalently bound hydrogen atom with one or more 
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other atoms, groups of atoms, or molecules into an aggregate structure that is 
sufficiently stable to make it convenient for the chemist to consider it as an 
independent chemical species”14. Hydrogen bonds can be either intermolecular - 
between molecules or intramolecular when the interaction takes place within 
different parts of a single molecule. The energy of a hydrogen bond depends on a 
number of parameters such as the nature of the donor and acceptor atoms which 
constitute the bond, their geometry, and environment.15 The energy of a 
hydrogen bond can vary between 0.2 and 40 kcal/mol.15 Based on the energies of 
hydrogen bonds they can be subdivided into three groups: weak hydrogen bonds 
(the energy is less than 4 kcal/mol), moderate (4-15 kcal/mol) and strong (>15 
kcal/mol).16 The importance of weak and moderate hydrogen bonds should not 
be underestimated since they can play a significant role in the landscape of the 
non-covalent interactions in the lack of strong hydrogen bonds. To the most 
typically observed weak hydrogen bonds belong such interactions as C-H∙∙∙N, C-
H∙∙∙O, C-H∙∙∙X (X= Cl, F), and N-H∙∙∙π.17 This fact indicates that a hydrogen bond is 
to some extent stronger than a van der Waals interaction, but it is weaker than 
covalent or ionic bonds.  
One more important aspect that influences the strength of a hydrogen bond is 
the pKa values of both hydrogen bond donor and acceptor.18-20 If the ionic charge 
is present on the donor and acceptor of a hydrogen bond, the electrostatic 
dipole-dipole component of hydrogen bonding is enhanced. The hydrogen bonds 
of this type are called “Charge Assisted hydrogen Bonds” 21-23 They are usually 
obtained via proton transfer in acid-base reactions. “Charge-Assisted Hydrogen 
Bonds” integrate the directionality of a hydrogen bond with the strength of 
Coulombic forces. 
It is an inevitable fact that hydrogen bonds being both an electrostatic and a 
directional interaction play a crucial role in crystal engineering.16, 24-26 However, 
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this is not the only type of interactions that can be used in the construction of 
new crystalline solids. Halogen atoms can work as acceptor sites resulting in the 
interaction called halogen bonding.13, 27, 28  
According to Metrangolo et al. “a halogen bond occurs when there is evidence of a 
net attractive interaction between an electrophilic region associated with a 
halogen atom in a molecular entity and a nucleophilic region in another, or the 
same, molecular entity”.29 Thus, halogen bonding is a particular non-covalent 
interaction in which a halogen atom acts as electrophilic species with electron 
donors.27  
Like hydrogen bonds, halogen bonds can be also used to control recognition, self‐
assembly, and aggregation processes in the solid.27 The energies of halogen bonds 
are dependent on the interacting partners and vary significantly from ~2.5 
kcal/mol for weak interactions (for instance N···Cl contacts30) to ~36 kcal/mol – 
the very strong interaction (in the I2···I
– adduct31).28 The notable energies of 
certain halogen bonds allow these interactions to prevail over other non-covalent 
interactions such as dipole-dipole interactions, π–π stacking, etc.32 Halogen bonds 
are particularly directional interactions.33 Some of the most common halogen 
bond synthons are given in scheme 1.1-2.34, 35 
 




The understanding of all the possible intra- and intermolecular interactions does 
not guarantee the predictability of the outcome of a crystallization process. 
Especially, the prediction becomes more difficult if more than one molecular 
and/or ionic building block is involved in the crystallization process. Figure 1.1-1 
represents the possible outcomes. The crystallization may result in the formation 
of an amorphous product, polymorphs11, 26, 36-38, hydrates37, 38, solvates37, 38, salts, 
molecular39-42 or ionic43-45 co-crystals, and solid solutions.46-49 
 
 
Figure 2.2.1-1 Schematic representation of the structural relationship between polymorphs, 






The fundamental physicochemical properties of crystalline materials depend on 
the arrangement of the molecular/ionic building blocks within the solid. 
Consequently, changing the disposition and/or interactions between these 
components can have a direct influence on the properties of the particular solid.50 
In attempt to improve the solid-state properties of a given compound, the 
scientists working in the field of molecular crystal engineering have always been 
interested in such a phenomenon as crystal polymorphism: the ability of a solid 
material to exist in multiple forms or crystal structures51. Having different 
structures polymorphs can possess different thermal, solubility, optical and 
electrical properties. The search for the solid form landscapes of molecules of 
interest is typically aimed to determine the crystalline form(s) performing 
predictably at the given conditions.38 Industry is always interested in robust 
process development and usually gives preference to the most 
thermodynamically stable form that can be manufactured consistently.52 
Currently, the computational prediction is not capable of foretelling the exact 
number of observable polymorphic forms of even the simplest molecules.53 
Therefore, for the search of new polymorphs high-throughput screening methods 
are commonly used.54 Normally various crystallization techniques are used to 
search for all the possible solid forms of the investigated compounds 
(polymorphs, hydrates, and solvates) and afterwards the most stable crystal form 
is determined.55 Unfortunately, even enormous efforts invested into a properly 
elaborated and implemented screening test do not guarantee that a new crystal 
form will not suddenly emerge afterwards.51 And sometimes the unexpected 
discovery of such a form can create a lot of problems for the manufacturer since 
its physicochemical properties might be significantly different from the produced 
form. The lack of predictability of formation of new polymorphs, hydrates and 
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solvates can be explained by insufficient level of comprehension of the 
mechanisms of nucleation and crystal growth.56 
However, the existence of more than one polymorphic form of the investigated 
compound can be of use for the industry. Since the phenomenon of 
polymorphism is not predictable, it meets all the requirements of a patent: 
novelty, non-obviousness, and usefulness for the industrial application. 57-60 Due 
to this fact, polymorphism has recently become the principal investigation area 
for the solid-state scientific community in the pharmaceutical, agrochemical and 
pigment industries.11, 58, 61-64 
The extent of polymorphism of the compound of interest is limited to the handful 
of its various crystalline forms.65 Despite the fact that different polymorphic forms 
can vary in some physicochemical properties this variation rate is limited due to 
the presence of only one componenet.66 However, in some cases even relatively 
minor changes can have a crucial effect on a particular property of the 
investigated compound. Perhaps, the most famous case of the effect of 
polymorphism is the case of about the Norvir® (ritonavir) – antiretroviral 
medication used to treat AIDS.67 In the development process of this drug only one 
polymorphic form was found. However, during the dissolution tests some lots of 
capsules showed much lower solubility characteristics. As it was found out, this 
phenomenon was caused by a “spontaneous” appearance of a more stable 
polymorphic form.68 As a result, the medication was removed from the market 
causing the loss of millions of dollars and heavy consequences on patients.69 After 





1.3. Multicomponent systems 
Multicomponent crystalline assemblies are relevant targets in the quest for novel 
solid forms exhibiting enhancement of physicochemical properties such as 
solubility, intrinsic dissolution rate, morphology, thermal and hydration stability 
compared to those of the separate components. Due to their potential to tune 
these crucial properties, multicomponent crystalline solids are of interest in a 
variety of applications (pharmaceuticals, pigments, high energetic materials, 
nutraceuticals, agrochemicals, cosmetics etc.).71-74 To date, solid-state chemists 
can employ a number of strategies to modify the chemical and physical solid-state 
properties of materials of interest (see fig. 1.1-1): the formation of polymorphs, 
salts, hydrates, solvates, molecular and ionic co-crystals, and solid solutions.50 The 
use of multicomponent systems can provide a large variety of constituents in the 
solid form and each of them has a direct impact on the properties of the 
particular solid.50 
The most well-established approach in the formulation of a new multicomponent 
crystalline solid with enhanced physicochemical properties is the formation of a 
salt.75-78 The main limitation of salts is that the compound of interest must contain 
ionizable (basic or acidic) moieties.79, 80 A different pathway can be the formation 
of a co-crystal.36, 40, 50, 81, 82 The exact definition of a co-crystal is still a matter of 
debate.41, 42, 82 However, there are, at least, three broad commonalities that are 
agreed upon by the majority of the scientists working in the field of crystal 
engineering.40 First, co-crystals are constructed from discrete neutral molecular 
species. This statement excludes all solids containing ions, namely salts and 
complexes of transition-metal ions. Second, co-crystals are constituted of 
reagents that are solids at ambient conditions. This assertion allows to distinguish 
co-crystals from solvates and hydrates as well as from clathrates or inclusion 
compounds with a solvent/gas molecule as a guest component.40 Finally, the 
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components of co-crystals should be present in well-defined stoichiometric 
amounts forming structurally homogeneous crystalline solids.40 This statement 
allows drawing a borderline between co-crystals and solid solutions. The main 
advantage of co-crystals over salts is the fact that, in principle, any molecule could 
potentially form a co-crystal regardless of the presence of any ionizable moieties 
in its structure.50 
Depending on the nature of a co-former, the co-crystals can be divided into 
“molecular” or “ionic”.76 The former are composed of at least two neutral co-
formers in a stoichiometric ratio. The components of such a co-crystal are 
typically held together by hydrogen and/or halogen bonds and π-π stacking. The 
term “ionic co-crystal” (ICC) was introduced by our research group.43 Initially the 
term was used to define the co-crystals formed by a neutral organic molecule and 
an inorganic salt of a non-transition metal. The main interactions in such organic–
inorganic systems are those established by metal cations with the organic 
moieties (typically, oxygen or nitrogen atoms donate electrons towards the metal 
cation). The anions, typically but not exclusively halides, form hydrogen bonds 
with the hydrogen donor groups on the organic moieties.44 The interactions of 
ions with the organic molecules resemble the ones between solvent and ions in 
solution or in solid solvates.43 These ICCs could be considered as complexes of 
organic type ligands and metal cations.44 
To date, the use of this term has been extended towards the co-crystals of neutral 
molecules with organic or organic-inorganic salts.44 Generally speaking, ICCs do 
not meet the requirements of the co-crystals mentioned above since one of the 
co-formers is not neutral. However, they do not meet the requirements of the 
salts either since no proton transfer took place between the molecule of interest 
and the co-former. Consequently, the ICCs lie on the borderline between salts and 
co-crystals. As a result, in the literature we can often meet the compounds of 
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such a type with different names such as a “co-crystal of a salt” of “salt co-
crystal”.80 
Even the distinction between a salt and a co-crystal is not always straightforward. 
Thus, if there is a hydrogen bond between the molecule of interest and the co-
former sometimes it is not possible to determine the position of the proton in a 
base – acid pair system. For instance, in the hydrogen bond formed by a 
carboxylic group and an amine the position of a proton depends on the relative 
acid– base strength and, obviously, on the temperature. The main condition for 
the formation of a salt in the acid-base reaction is that the value of ΔpKa = 
pKa(Acid)-pKa(Base) should be greater than 2 or 3, whereas for ΔpKa < 0 a co-
crystal is generally formed.79, 83-86 
An alternative route in the design of crystalline materials with desired properties 
is to prepare multicomponent systems of variable stoichiometric ratios – solid 
solutions.47, 48, 87-90 These multicomponent solids are considered a useful tool for 
modifying physicochemical properties.91-93 Crystalline solid solutions or organic 
alloys can be characterized by a structural disorder that permits the variation of 
the ratios of their components in continuum.49 Consequently, the stoichiometric 
ratio of solid solutions is not usually limited to an integer or rational number. 
Since the stoichiometry of the components of such systems can be varied in 
continuum, at least in a certain composition range, taking control over their ratios 
becomes the crucial aspect not only for a fine tuning of solid-state 
physicochemical properties, but also for their predictability.49 Especially, the 
continuous variation of the amount of components of a solid solution can impact 
on the thermal properties. Quite often a solid solution exhibits properties which 
are between those of the pure components. However, sometimes new 
unexpected properties can arise.49, 87 Solid solutions are good candidates to 
understand structure – properties relationship. In principle, it should be possible 
12 
 
to follow the change of the physicochemical properties upon varying the 
stoichiometric ratio of the components. 
Unlike co-crystals which can be formed by a virtually infinite amount of molecular 
and/or ionic building blocks, solid solutions required a number of prerequisites. In 
this respect, the similarity in chemical structure and, preferably, in 
supramolecular arrangement in the crystals of a single component is typically the 
major precondition to obtain a solid solution.47, 48, 89, 90 If the molecules are quite 
similar in size and shape, there is a chance that they can become miscible in a 




1.4. Methods and techniques used for the characterization of solid 
products: 
 Single Crystal X-ray Diffraction (SCXRD), the main technique used for 
structure determination;  
 X-ray Powder Diffraction (XRPD). This technique allowed characterizing the 
bulk material. In co-crystallization experiments it was mainly used to 
determine whether the change of the phase took place, whether there 
were any new peaks different from those of the starting materials and, if 
so, whether some traces of the starting materials were still present in the 
bulk. When it was not possible to grow the single crystal of suitable quality 
to solve the structure using SCXRD, XRPD was applied for this purpose.  
 Variable Temperature X-ray Powder Diffraction (VT XRPD). This technique 
was used to follow the possible changes in the crystalline structure of the 
investigated solids upon change of the temperature;  
 Differential Scanning Calorimetry (DSC), a thermoanalytical technique used 
to detect phase changes (dehydration/desolvation, polymorphic transition, 
melting);  
 Thermogravimetric Analysis (TGA). This technique applied to quantify the 
mass loss of the sample upon heating;  
 Hot-Stage Microscopy (HSM). The technique which was used for 
preparation of the crystals from melt and for visual estimation of the effect 
of the temperature on the investigated solids. 
 Intrinsic dissolution rate (IDR) analysis. This technique was used to 
determine the speed with which the compound is released from the crystal 
lattice into solution;  
 Solubility test. This technique was used to determine the maximum 
quantity of compounds capable of dissolving in a given amount of solvent.  
14 
 
 Ternary phase diagram (TPD) construction. This technique was used to 
determine the most thermodynamically stable phase for a given 
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2. CHAPTER II - MOLECULAR SOLID SOLUTIONS 
 
2.1. Overview 
The investigation of multicomponent crystalline solids is a well-studied aspect of 
modern crystal engineering.1-5 Solid solutions or organic alloys are 
nonstoichiometric multicomponent crystals in which two or more molecules are 
mutually miscible (at least in a certain composition range) in a solid. They are 
typically characterized by a structural disorder enabling the variation of the 
stoichiometric ratio of their components in continuum.4 These multicomponent 
solids are considered a useful tool for modifying physicochemical properties.3, 6, 7 
Though solid solution often exhibit properties which are between those of the 
pure components, in some cases the formation of a solid solution may result into 
appearance of some new unexpected properties.4, 8 
To date, the solid solutions formation is still quite unpredictable. Typically, the 
solid solutions of organic molecules are formed by molecules similar in size. 
Concepts of isomorphicity and isostructurality are considered to be a prerequisite 
to identify potential solid solutions. 
The investigation of solid solutions of organic molecules in our research group 
started with the preparation of disordered co-crystals between o-toluic acid and 
o-chlorobenzoic acid9 (fig. 2.1-1). 
  




Figure 2.2.1-1  o-methylbenzoic and o-chlorobenzoic acids (top) and the disordered co-
crystal formed by their interaction - TOJFUU9 (bottom) 
 
Methyl and chloro- groups have similar shape and size with van der Waals 
volumes of ca. 19 Å3 and 21 Å3 correspondingly10. The obtained co-crystal is 
composed of quasi-isostructural molecules differing by a chlorine group replacing 
a methyl group or vice versa and it is characterized by the chloro-methyl 
exchange. A similar approach appeared to be useful also for p-methyl and p-
chlorobenzyl alcohols (p-MeBA and p-ClBA correspondingly) (fig.2.1-2)11. The 
quasi-isostructurality of the investigated molecules led to the formation of 
multicomponent solids isomorphous with one of the reagents - with the crystals 
of p-ClBA. Later on, this study has been extended with the bromine analogue(p-
BrBA)12: the formation of binary and ternary solid solutions and the influence of 
composition variation on the melting point of the obtained multicomponent 




Figure 2.2.1-2 Compounds used for the preparation of binary and ternary solid solutions. 
 
The following step in the investigation of the possibility to obtain solid solutions 
was to try and mix barbituric with thiobarbituric and cyanuric with trithiocyanuric 
acids (fig. 2.1-3). The idea was to use the relative similarity of carbonyl and 
thiocarbonyl groups to check whether they would be capable of forming solid 
solutions.  
 
Figure 2.2.1-3 a) Barbituric acid (BA); b) Thiobarbituric acid (TBA); c) Cyanuric acid (CA); d) 
Trithiocyanuric acid (TCA). 
21 
 
The choice of the molecules was not random since both barbituric and 
thiobarbituric acids were widely investigated by our research group: the search 
for new polymorphic forms,13-15 molecular16 and ionic17-19 co-crystals. 
The obtained results showed that it was possible to form solid solutions only with 
the first pair of the investigated acids – BA and TBA, whereas the mixing of CA 
with TCA regardless of the stoichiometry implied always led to the physical 
mixture of the starting materials. Actually, the obtained results lie within the 
concepts suggested by a latter study provided by Bucar et al.20: isostructural 
crystals could be obtained via interchanging carbonyl with thiocarbonyl groups 




2.2. Alloying barbituric and thiobarbituric acids: from solid solutions 
to a highly stable keto co-crystal form 
 
 





2.2.1. Supporting Information 
 
The link to the supporting information is reported here: 
http://www.rsc.org/suppdata/c6/cc/c6cc06615a/c6cc06615a1.pdf 
 
EXPERIMENTAL PART  
 
Solution Synthesis. All reactants and reagents were purchased from Sigma-Aldrich and used 
without further purification. Reagent grade solvents and bi-distilled water were used. 
All the solid solutions of BA and TBA acids with general formula BAxTBA1-x were obtained by 
dissolution of the x and 1-x quantities of the starting materials (see SI-Table 1) in 20 mL of 
boiling EtOH; the solution was left to evaporate at room temperature. 
 
SI-Table 1. Quantities of reagents employed in the crystallizations from solution. 
BA:TBA ratio BA, mg (mmol) TBA, mg (mmol) 
BA0.2TBA0.8 25.6 (0.2 mmol) 115.3 (0.8 mmol) 
BA0.3TBA0.7 38.4 (0.3 mmol) 100.9 (0.7 mmol) 
BA0.4TBA0.6 51.2 (0.4 mmol) 86.5 (0.6 mmol) 
BA0.5TBA0.5 64.0 (0.5 mmol) 72.1 (0.5 mmol) 
BA0.6TBA0.4 76.8 (0.6 mmol) 57.7 (0.4 mmol) 
BA0.7TBA0.3 89.7 (0.7 mmol) 43.2 (0.3 mmol) 
BA0.8TBA0.2 102.5 (0.8 mmol) 28.8 (0.2 mmol) 
 
Solid State Synthesis. BA0.5TBA0.5 was also obtained by kneading either thiobarbituric acid form 
I (keto-form) with ethanol, or thiobarbituric acid form IV (keto-enol form) with acetonitrile. 1 
mmol of BA and TBA were kneaded for 20 minutes in a Retsch MM200 ball miller, operated at a 
frequency of 20 Hz, in the presence of a few drops of the corresponding solvent.  
 
Crystal structure determination. Single-crystal data for BAxTBA1-x (x≥0.5) was collected at RT on 
an Oxford X’Calibur S CCD diffractometer equipped with a graphite monochromator (Mo-Kα 
radiation, λ = 0.71073 Å). Data collection and refinement details are listed in Table SI-S2. The 
program SHELX9721 was used for structure solution and refinement on F2. The program Platon22 
was used to calculate intermolecular interactions. Schakal9923 was used for molecular graphics. 
In BAxTBA1-x (x≥0.5) the S and O atoms (indicated by an arrow in Figure SI-1) of each 
24 
 
independent molecule were treated as disordered over two positions: the occupancy factor 
was first refined by keeping the isotropic thermal parameters fixed, than the occupancy factor 
was fixed and both oxygen and sulphur atoms were refined anisotropically. All non-hydrogen 
atoms were refined anisotropically. HCH and HNH atoms were added in calculated positions and 
refined riding on their respective carbon or nitrogen atoms.  
Crystal data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or 
from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB21EZ, UK; fax: 
(+44)1223-336-033; or e-mail: deposit@ccdc.cam.ac.uk). CCDC numbers 1498572 (BA0.5TBA0.5), 
149574 (BA0.6TBA0.4) and 149573 (BA0.7TBA0.3). 
 
SI-Table 1. Single crystal data for the BxTBA1-x solid solutions with x ≥ 0.5, and comparison with data for BA form II 
at room temperature
24 
and TBA form I [THBARB]
25
 at room temperature.  




BA0.5TBA0.5 BA0.6TBA0.4 BA0.7TBA0.3 BA0.8TBA0.2
a 
BA form II 
RT
24 
Formula C4H4N2O2S C4H4N2O2.5S0.5 C4H4N2O2.6S0.4 C4H4N2O2.7S0.3 C4H4N2O2.8S0.2 C4H4N2O3 
fw 144.15 136.12 134.52 132.91 131.31 128.09 
Cryst. System monoclinic monoclinic monoclinic monoclinic monoclinic monoclinic 
space group P21/c P21/c P21/c P21/c P21/c P21/c 
Z, Z’ 8, 2 8, 2 8, 2 8, 2 8, 2 8, 2 
a (Å) 8.450(10) 8.533(1) 8.4662(13)  8.4569(9) 8.321(7)  8.199 
b (Å) 13.140(20)  13.0141(10) 12.9681(12) 12.9400(10) 12.797(6) 12.613 
c (Å) 10.420(10) 9.6918(12) 9.6819(11) 9.5593(9) 9.698(6) 9.823 
α (deg) 90.00 90.0 90.0 90.0 90.0 90.00 
β (deg) 92.70 92.131 92.490(14) 92.626(10) 93.70(6) 95.7 
γ (deg) 90.00 90.0 90.0 90.0 90.0 90.00 
V (Å
3
) 1155.679 1075.5(2) 1062.0(2) 1045.00(17) 1030.5(12) 1010.8 
Dcalc (g/cm
3
) - 1.681 1.683 1.690 - - 
μ (mm
-1
) - 0.324 0.294 0.256 - - 
Measd reflns - 4693 4603 4818 - - 





- 0.0856 0.1059 0.0743 - - 
wR2 (all data) - 0.1552 0.2839 0.1604 - - 
 
a
 Unfortunately, despite many attempts at growing good quality single crystals of BA0.8TBA0.2, the quality of the 
best data set collected still does not reach the standard required for data deposition; however, the space group 
was ascertained with confidence, the sulphur contribution was evidenced and the cell volume was found to fit well 






































TBA 100% x BA 100%
 
Figure SI-1. Cell parameters variation (single crystals, room temperature data) on passing from TBA form I to BA 




    
 
Figure SI-2. The hydrogen bonding pattern observed in BA form II (top left, BARBAC02, O atoms of independent 
molecules shown in red and blue) and in TBA form I (top right, THBARB, S atoms of independent molecules shown 
in yellow and orange) is also maintained in the solid solutions; here the packing for the BA0.5TBA0.5 co-crystal is 
shown (bottom), with the two large hydrogen bonded rings forming 2D parallel planes perpendicular to the 
crystallographic ac-plane. 
 
X-ray powder diffraction. Room temperature X-ray powder diffraction (XRPD) patterns were 
collected on a PANalytical X’Pert PRO automated diffractometer equipped with a X’celerator 
detector in the 2θ range 3–50° (step size 0.0334, time/step 30.480 s, VxA 40x40). Data analyses 
were carried out using the Panalytical X’pert Highscore Plus program. The identity between the 
bulk material obtained via olution and solid-state processes was verified by comparing 
calculated and observed powder diffraction patterns. The program Mercury26 was used for 
simulation of X-ray powder patterns on the basis of single crystal data, while the program 
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PowderCell27 was used to simulate a powder pattern on the basis of cell parameters – thus to 
identify the angular position of relevant peaks – for BA0.8TBA0.2 and for BA form II at room 
temperature, for which only single crystal cell parameters were available.  




















Figure SI-3. Comparison of experimental (crystallizations from solution) and simulated patterns (on the basis of 
single crystal data) for BA0.5TBA0.5, BA0.6TBA0.4  and BA0.7TBA0.3. 
 
 
Fig. SI-4. Experimental XRPD patterns for BAxTBA1-x solid solutions with x ≤ 0.5: expanded section showing a 
general shift (analogous to what observed for the solid solutions with x > 0.5) of the peaks towards lower angles, 
on increasing the percentage of TBA, with respect to the BA0.5TBA0.5 co-crystal (red line). 
 
 
Figure SI-5. Comparison between the XRPD pattern measured on the products obtained by crystallizing from 
MeOH BA form II and THBARB form I in 40:60 (top, green line), 30:70 (middle, blue line) and 20:80 (bottom, black 
line) molar ratios: BA0.5TBA0.5 is formed in all cases, together with unreacted TBA. 
 













































Figure SI-6 Comparison between the XRPD pattern measured on the product obtained by kneading BA form II and 
THBARB form I in 1:1 molar ratio in the presence of a few drops of CH3CN and (top, blue line) and the simulated 
pattern pattern (on the basis of single crystal data) for BA0.5TBA0.5. 
 
 
Figure SI-7. Comparison between the XRPD experimental patterns measured after 3 months of standing in open air 
at ambient conditions on BA0.7TBA0.3 (blue line) and BA0.7TBA0.3 (green line) and the calculated pattern for 
BA0.5TBA0.5: the solid solutions are still unchanged. 
 











































____ kneading product  
         (CH3CN, BA:TBA 1:1), exp. 




Figure SI-8. Comparison between the XRPD experimental patterns measured after 1 month of standing in open air 
at ambient conditions on BA0.3TBA0.7 (blue line) and BA0.4TBA0.6 (black line) and the calculated pattern for 
BA0.5TBA0.5: the solid solutions have converted into the co-crystal BA0.5TBA0.5 plus an excess of TBA form I. 
 
Hot Stage Microscopy (HSM). HSM measurements were carried out using a Linkam TMS94 
device connected to a Linkam LTS350 platinum plate. Images were collected with the imaging 
software Cell, from a Visicam 5.0 stereoscope. Images (100x) were taken with an Olympus 
optical microscope. 
 
Differential Scanning Calorimetry (DSC) 
DSC measurements were performed with a Perkin–Elmer Diamond. The samples (3-10 mg) 
were placed in open aluminum pans, and the heating was carried out at 10 °C min−1 in N2 
atmosphere.  
Peak temperatures (°C) are indicated in all DSC heating traces shown in the following.  
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Figure SI-11. DSC trace of TBA form I 
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Figure SI-16. DSC trace of the product of crystallization of BA form II and TBA form I in 50:50 stoichiometric ratio. 
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Figure SI-17. DSC trace of the product of crystallization of BA form II and TBA form I in 60:40 stoichiometric ratio. 
 
 




Figure SI-19. DSC of a 1:1 physical mixture of BA form II and TBA I, showing formation of the BA0.5TBA0.5 co-crystal 
upon melting of the two components. 
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3. CHAPTER III - IONIC CO-CRYSTALS 
 
3.1. Overview 
Crystalline solid materials formed by a neutral molecule and a salt have been 
known for long, however, only recently they have been defined as “ionic co-
crystals” (ICCs). The term was coined by our research group.1 Initially, the term 
was employed only for the co-crystals formed by a neutral organic molecule 
and an inorganic salt of an alkali or alkaline earth metals (mainly halides). Later 
on, this term has also been used for the co-crystals of neutral molecules with 
organic or organic-inorganic salts.2-4 
This chapter is focused on the design, preparation and evaluation of co-crystals 
formed by organic molecules and inorganic salts –alkali and alkaline earth 
metal halides. The principal interactions in such systems are those established 
by metal cations with the organic groups – generally oxygen or nitrogen atoms 
capable of donating electrons. The anions (halides), in turn, form hydrogen 
bonds with the hydrogen donor groups on the organic moieties.2 Solid 
materials formed by organic-inorganic systems are of interest for 
pharmaceutical, agrochemical, food and other industries since they could 
combine the physicochemical properties of the individual components.5-9 They 
have proved to be advantageous to obtain modified solid-state properties with 
respect to those of the separate components (improved thermal stability, 
different solubilities and intrinsic dissolution rates, reduced hygroscopicity, 
etc.).10-17 For these reasons ICCs are attracting the interest of researchers 
working in the field of co-crystals and utilizing the tools of crystal engineering 
to prepare multicomponent materials. 
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The investigation of ICCs formation performed during my PhD project can be 
subdivided into two general directions: 
1. The formation of ICCs aimed at modification of the physicochemical 
properties of interest (mainly intrinsic dissolution rate and solubility).  
2. The co-crystallization of inorganic salts with chiral compounds. The goal 
of this research was to investigate the possibility to apply co-
crystallization as a tool to either separate a particular enantiomer from a 
racemic mixture or to prevent its possible transformation into a different 
form. 
The detailed information on the ICCs formed by organic molecules and 









3.2. Ionic co-crystals of cyanuric acid with alkali halides 
 
3.2.1. Introduction 
The investigation of ICCs formation began with mechanochemical18, 19 co-
crystallization of thiobarbituric, cyanuric and trithiocyanuric acids (fig. 3.2.1-1) 
with the alkali halides. As it was already mentioned in the second chapter, 
barbituric and thiobarbituric acids were extensively studied by our research 
group for the possibility of existence of new polymorphic forms,20-22 
molecular23 and ionic1, 11, 24 co-crystals. 
 
Figure 3.2.1-1 a) Barbituric acid (BA); b) Thiobarbituric acid (TBA); c) Cyanuric acid (CA); d) 
Trithiocyanuric acid (TCA). 
 
In fact, the existence of the whole class of “ionic co-crystals” was accidentally 
discovered when pellets of barbituric acid (BA) with potassium bromide were 
prepared for IR spectroscopy.1 Consequently, the crystal structures of the 
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whole family of ICCs of BA with alkali bromides as well as with caesium iodide 
were established. In the obtained ICCs all three carbonyl groups of barbituric 
acids are involved in coordination with metal cations (fig. 3.2.1-2, BA·KBr·2H2O 
is given as an example). The bromides, in turn, form hydrogen bonds with NH-
groups and water molecules. 
  
 
Figure 3.2.1-2 The ionic co-crystal formed by barbituric acid and KBr - BA·KBr·2H2O (ref. 
code NAHQIY1). Hydrogen atoms of cyanuric acid are omitted and water molecules are 
marked in blue for the sake of clarity. 
 
The molecule of cyanuric acid (CA) could represent, in principle, an even more 
suitable target for ICCs formation compared to barbituric acid since it has three 
NH-groups which can form hydrogen bonds with halides. The obtained results 
(table 3.2.1-1) showed that our assumption was correct and CA formed ICCs 




Table 3.2.1-1 Mechanochemical preparation of ICCs of CA with alkali halides. 
 Cl Br I  
Li CA∙LiCl12 New* New* 
Na CA∙NaCl12 CA∙NaBr 
CA∙NaBr∙2H2O 
New* 
K No ICC CA∙KBr CA∙KI∙2H2O 
Solved by SG 
Rb CA2∙RbCl CA∙RbBr CA∙RbI 
Cs CA2∙CsCl CA∙CsBr No ICC 
*New phase was detected using XRPD, but the structure was not solved. 
 
Unfortunately, the co-crystallization of thiobarbituric and trithiocyanuric acids, 
in turn, was much less successful: only one ICC of TBA with caesium bromide 
was obtained and structurally characterized. The idea was to understand how 
the virtual substitution of one (TBA) and all three (TCA) carbonyl groups with 
thiocarbonyl could impact the co-crystallization propensity of the 
corresponding organic molecule. Especially, such comparison was considered 
valuable after the possibility of formation of solid solutions between BA and 
TBA was discovered.25 
The co-crystallization of cyanuric acid with the majority of alkali halides 
resulted into formation of ionic co-crystals (table 1). Quite surprisingly, the 
majority of the obtained ICCs appeared to be anhydrous. The anhydrous nature 
of ICCs with LiCl and NaCl is rather unusual. The majority of ICCs of alkali 
halides in the CSD26 are hydrated, especially the ones formed by lithium or 
sodium cations - high to medium charge density alkali ions. Most likely, the 
formation of anhydrous ICCs can be explained by the peculiar structure of CA: it 
41 
 
is small, highly symmetrical and capable of both hydrogen bonding to the 
anions and cation complexation via O-atoms. 
Cyanuric acid has a very low water solubility.12 With the aim to increase its 
solubility NaCl·CA was chosen to perform the measurements of the intrinsic 
dissolution rate – the rate at which the compound is released from its crystal 




3.2.2. Anhydrous ionic co-crystals of cyanuric acid with LiCl and NaCl 
The results of the co-crystallization of CA with LiCl and NaCl and the impact of 








3.2.2.1. Supplementary Information 
 




Materials and instrumentation 
All reagents and solvents used in this work were purchased from Sigma-Aldrich and 
used without further purification. 
 
Solid State Synthesis 
ICCs of cyanuric acid were obtained by kneading CA (1 mmol) and the 
corresponding co-former (1 mmol) for 30-60 minutes in a Retsch MM200 ball miller, 
operated at a frequency of 25 Hz, in the presence of a few drops of solvent (ethanol 
and water for CA·NaCl, methanol for CA∙LiCl). CA·LiCl was also obtained by manual 
grinding, but its preparation of CA∙LiCl was more difficult due to the high 
hygroscopicity of LiCl, and 4 to 5 cycles of grinding in a mortar (up to 5 minutes) 
followed by drying in the oven (15-20 minutes) were necessary to get a pure product. 
X-ray powder diffraction measurements  
Room temperature X-ray powder diffraction (XRPD) patterns were collected on a 
PANalytical X’Pert PRO automated diffractometer with transmission geometry 
equipped with Focusing mirror and Pixcel detector in the 2θ range 5–90° (step size 
0.0130°, time/step 118.32 s, VxA 40kV x 40mA). Data analyses were carried out 
using the Panalytical X’pert Highscore Plus program. The identity between the bulk 
material obtained via solution and solid-state processes was always verified by 
comparing calculated and observed powder diffraction patterns. 
Synchrotron radiation-XRPD measurements of CA·LiCl and CA·NaCl were performed 
at the Swiss Light Source (SLS) Material Science (MS) Powder Diffraction (PD)27 end 
station with a nominal photon energy of 17KeV. Fine Si640D NIST standard refinement 
returned a wavelength of 0.709703(2)Å and a residual Zero Error of 2 = 0.0048(4)°. 
Data were collected with a 1D Mythen II detector28 in the range 2-120° 2θ, with intrinsic 
step size of 0.0036 (2θ). Samples were loaded in 0.5 mm glass capillaries and spun at 
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4Hz during the measurement. Multiframing data were recorded in transmission with an 
exposure time of 5 seconds to avoid radiation damage; the raw data were then 
individually inspected before being merged together and flat field corrected. 
 
Structural determination of CA∙LiCl. 
Laboratory data were preliminarily used to determine the crystal structure. Powder 
diffraction data were analysed with the software X’Pert HighScore Plus29 and unit cell 
parameters were found using DICVOL4 or DICVOL algorithms. Initially CA∙LiCl was 
indexed in the cubic system with a unit cell volume of 161.79 Å3. The cell volume 
corresponds to the volume of 1x(LiCl C3N3O3H3), hence the structure was solved in 
the triclinic space group P1 by simulated annealing, performed with EXPO2014,30 
using Li and Cl atoms, and one molecule of cyanuric acid. Ten runs for simulated 
annealing trial were set, and a cooling rate (defined as the ratio Tn/Tn-1) of 0.95 was 
used. The Platon31 ADDSYMM SHELX command was subsequently applied, and 
data were transformed into the trigonal space group R3m.  
The Rietveld refinement was subsequently performed with TOPAS 5.032 in the R3m 
space group on synchrotron data measurement in the range 2=6.6-70.5°. A shifted 
Chebyshev function with 10 parameters was used to fit the background and two extra 
peaks to describe the halos of the amorphous material. The peak shape was modelled 
for size and strain with the Gaussian and Lorentzian functions present in TOPAS 5.0 and 
the anisostropic peak broadening was modelled as described by Stephens.33 
The excess of LiCl used in the reaction was identified as LiCl·H2O monohydrate, 
which was refined on the basis of the known crystal structure (see Figure ESI-1).  
The refinement converged to  Rwp=4.89 %  and Rp= 4.63%. 
 
Figure ESI-1.: Rietveld analysis plot of CA∙LiCl. Red line is the calculated diffractogram, blue line is the 
observed diffractogram and grey line is the difference plot.  Blue and black tick marks corresponds to  
CA∙LiCl and LiCl∙H2O respectively.  Y-axis is reported as √𝑦. 
black tick marks: CA∙LiCl,  93.17 % 
blue tick marks:  LiCl∙H2O,   6.83 % 
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The powder pattern of CA∙NaCl was indexed in the hexagonal system, space group 
P63mc, with a volume cell of 325.231 Å
3 and a plausible solution was found with 
EXPO 2014 with the simulated annealing algorithm.  The structure was analysed with 
Platon, ADDSYMM SHELX command was applied and a unit cell of a higher 
symmetry was found. Afterwards, the structure described with P63/mmc symmetry 
was used for Rietveld refinements in the range 2=5-90°, which were performed with 
the software TOPAS 5.0. The background was described by modelling the empty 
capillary and by the Chebyshev function with 2 parameters. The peak shape was 
modelled for size and strain with the Gaussian and Lorentzian functions present in 
TOPAS 5.0. 
A small quantity of NaCl present was identified in the product pattern, and its profile 
was refined on the basis of the known crystal structure (see Figure ESI-2).  
The refinement converged to  Rwp=4.55 %  and Rp= 4.03%. 




Figure ESI-2. : Rietveld analysis plot of CA∙NaCl. Red line is the calculated diffractogram, blue line is the 
observed diffractogram and grey line is the difference plot.  Black and blue tick marks corresponds to  
CA∙NaCl and NaCl respectively.  Y-axis is reported as √𝑦. 
  
black tick marks: CA∙NaCl, 99.60 % 




Table ESI-1. Structural data for CA·LiCl and CA·NaCl. 
 CA∙LiCl CA∙NaCl 
Formula C3H3N3O3LiCl C3H3N3O3NaCl 
-1) 171.47 187.52 
Crystal system Trigonal Hexagonal 
Space group  R3m P63/mmc 
Z 3 2 
a (Å) 7.7079(1) 7.6807(1) 
b (Å) 7.7079(1) 7.6807(1) 
c (Å) 9.4483(3) 6.3662(1) 
α (°) 90.0 90.0 
β (°) 90.0 90.0 
γ (°) 120.0 120.0 
V (Å3) 486.1(1) 325.23(1) 
R_wp 4.9 4.5 
 
The programs Vesta34, Schakal35 and Mercury36 were used for graphical 
representations of the structures. Crystal data can be obtained free of charge via 
www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic 
Data Centre, 12 Union Road, Cambridge CB21EZ, UK; fax: (+44)1223-336-033; or e-
mail: deposit@ccdc.cam.ac.uk). CCDC numbers 1524847 and 1524848 for CA·LiCl 
and CA·NaCl, respectively. 
Thermogravimetric Analysis (TGA) 
TGA measurements were performed using a Perkin-Elmer TGA7 in the temperature 
range 30-400 °C under an N2 gas flow, at a heating rate of 5 °C min
-1. 
Intrinsic dissolution test for CA∙NaCl. 
Dissolution rate in ultrapure water solution at room temperature was performed for 
cyanuric acid and CA∙NaCl. Measurements were carried out using a Varian Cary 50 
spectrophotometer equipped with a fiber optic dip probe. Absorbance of the solutions 
was continuously measured during 2 minutes. 
Solubility test for CA∙NaCl. 
A small amount of CA∙NaCl was weighed, and portions of it were added to a test tube 
containing 1mL of water at room temperature, and shaken until the solid was 
completely dissolved. The procedure was repeated until no more CA∙NaCl could be 
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dissolved. The remaining co-crystal was weighed and the difference with the initial 
quantity calculated as the amount of the co-crystal dissolved. The experiment was 
repeated 3 times and the average value was used.  
 
Fig. ESI-3. TGA trace for CA·LiCl as obtained from the solid-state reaction. The first weight loss corresponds to 
excess water adsorbed on the crystals surface, due to the excess of LiCl used in the reaction, which, upon 
desiccation in the oven, forms monohydrated LiCl (see Fig. ESI-1). The upper solid line, parallel to the x-axis and 
used to mark the first loss of water, incorrectly suggests that a plateau is present between 37 and 50°C. For this 
reason the derivative curve has been traced (dotted curve), which shows how water release is active already at 
37°C, i.e. at the beginning of the measurement (thus indicating loss of surface water, that is followed by release of 




Fig. ESI-4. TGA trace for CA·NaCl as obtained from the solid-state reaction.  
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3.2.3. Ionic co-crystals of cyanuric acids with the rest of alkali 
halides. 
Cyanuric acid easily forms ionic co-crystals with alkali halides (see introduction, 
table 3.2.1-1). All ICCs were obtained by mechanical mixing of solid CA and of 
the alkali salts by kneading the solid mixture with the addition of a small 
quantity of solvent. Similar to ICCs of cyanuric acid with LiCl and NaCl, 
crystallization from solvent (ethanol, methanol and water) failed to yield 
crystals suitable for single crystal investigation. The only exception was 
CA∙KI∙H2O, which yielded single crystals suitable for structure determination. 
The lack of single crystals motivated us to determine the structures from 
powder diffraction data alone. 
As it was observed for CA·LiCl and CA·NaCl, the majority of the ICCs discussed 
here are anhydrous. This phenomenon as such is rather unusual since the 
majority of ICCs of alkali halides prepared this far tend to form hydrates1, which 
in some cases can be subsequently dehydrated.24 We attribute this difference 
to the peculiar structure of CA, which is small and highly symmetrical affording 
optimal packings with spherical ions without a need to fill the metal cations 
coordination sphere with water molecules, as it will be apparent in the 
following. 
 
The interaction of CA with alkali chlorides 
To start with, the ICCs of a general formula MCl (M = Li, Na, Rb, Cs) can be 
examined in details. The interaction of CA with alkali chloride salts formed by 
the smallest cations of the group resulted into formation of crystals of high 
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symmetry12. The peculiarities of the crystal structures of CA·LiCl and CA·NaCl 
have been already discussed in the previous chapter (3.2.2). 
The use of bigger cations (Rb+ and Cs+) results in a change of stoichiometry of 
the co-crystals with the doubling of the number of CA molecules involved in the 
crystal structures. As a result, isomorphous CA2∙RbCl and CA2∙CsCl were 






Figure 3.2.3-1 XRPD of CA2∙RbCl and CA2∙CsCl 
 
Both ICCs crystallize in the monoclinic system. Rb/Cs cation is coordinated by 
six different molecules of CA and with three Cl- anions (fig. 3.2.3-2). If we divide 
the molecule of a CA into three equal O=C–NH fragments it becomes obvious 
that two such fragments interact with RbCl whereas the third one interacts 




Figure 3.2.3-2 CA2∙RbCl. View down crystallographic a-axis (top); hydrogen bonds 
between CA2 molecules. Hydrogen atoms are not shown for clarity 
 
Interestingly, CA2∙RbCl and CA2∙CsCl showed different susceptibility towards 
moisture. The former appeared to be quite stable at room temperature 
whereas the latter adsorbed water from the atmosphere. Besides the fact that 
it became sticky, its XRPD pattern showed the presence of some new peaks (fig. 
3.2.3-3). Taking into account the fact that it was possible to reobtain the initial 
XRPD pattern upon heating the sample in the oven it could be assumed that 
those peaks correspond to the hydrated form of the ICC of CA with CsCl. 









2 / deg  
Figure 3.2.3-3 CA2∙CsCl. The comparison between XRPD patterns of CA2∙CsCl analysed 




Table 3.2.1-1 reports also an intriguing negative result. So far it has proven 
impossible to obtain an ICC of CA with KCl. Despite the numerous attempts to 
synthesize CA∙KCl, all our efforts appeared to be unsuccessful: the methods 
that yielded the other co-crystals (kneading with ethanol, H2O and methanol) 
failed to give the ICC of cyanuric acid with KCl. Attempts to introduce other 
alkali salts which formed ICCs with CA in a kind of pseudo seeding to induce the 
formation of CA∙KCl failed as well. In all cases (NaCl and KBr) the peaks of the 
corresponding co-crystals along with unreacted CA and KCl were observed. 
Taking into account the information given above one is brought to think that 
the cation size plays a crucial role. The K+ cation is, on the one hand, too big to 
form an ICC with CA in 1:1 ratio (as in the case of Li+ and Na +), while, on the 
other hand, it is still too small to form a co-crystal in 1:2 ratio similar to the 
ones of RbCl and CsCl.  
 
The interaction of CA with alkali bromides 
Ball milling preparations of ICCs with Br- as an anion were much faster than 
with the Cl- anion. For example, the reaction of a mixture NaCl (1 mole) and 
NaBr (1 mole) with CA (2 moles) yielded quantitative formation of CA·NaBr (1 
mole) within 15 minutes while CA (1 mole) and NaCl (1 mole) were still 
unreacted. 
All the ICCs with alkali bromide present a 1:1 stoichiometry. The co-
crystallization of cyanuric acid with LiBr resulted in the formation of a new 
phase. Unfortunately, we have not been able to solve its structure so far. 
However, based on the obtained XRPD pattern it can be asserted that its 
structure is completely different from CA∙LiCl. In addition, TGA analysis showed 
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that it contains solvent molecules in its structure and since the obtained XRPD 
patterns were identical regardless of the solvent applied (methanol, ethanol 
and water) it was assumed that the hydrated product CA∙LiBr∙nH2O (see fig. 
3.2.3-4) was formed. 
 
Figure 3.2.3-4 TGA traces of CA·LiBr·nH2O 
 
The interaction of NaBr with CA appeared to be dependent on the solvent 
applied. Ball milling of the equimolar quantities of sodium bromide with 
cyanuric acid using methanol or ethanol as a solvent resulted into the 
formation of anhydrous CA∙NaBr which is isomorphous (fig. 3.2.3-5 (a)) to 
CA∙NaCl (XAKSUA12). However, if the same experiment is performed using 
















The Na+ cation in CA∙NaBr∙2H2O as well as in CA∙NaBr shows octahedral 
coordination with three coordination sites used by molecules of CA and three 
filled by water molecules (Fig. 3.2.3-6). 
  
 
Figure 3.2.3-6 Na+ coordination in CA∙NaBr∙2H2O. Oxygens of water molecules are marked 
in green and blue for clarity. 
 
The interaction with bromide salts of larger alkali cations (K+, Rb+, Cs+) resulted 




Figure 3.2.3-7 K+ coordination in CA∙KBr 
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The co-crystallization of cyanuric acid with rubidium and caesium bromides 
produced the isomorphous co-crystals CA∙RbBr and CA∙CsBr. Figure 3.2.3-8 
represents the crystal structure of CA∙RbBr. As for the ICCs formed with sodium 
halides discussed above, the Rb+ cations of CA∙RbBr have also an octahedral 
coordination. However, contrary to what observed with Na+, Rb+ interacts with 
four oxygens of different CA molecules and two anions. 
 
 
Figure 3.2.3-8 Crystal packing of CA∙RbBr. View down crystallographic a-axis 
 
The interaction of CA with alkali iodides 
The investigation of interactions of CA with alkali iodide salts was more 
difficult. The reaction with LiI resulted in the formation of a new phase which 
was very hygroscopic. The interaction with NaI resulted into a new ICC, but its 
structure was not solved so far. The obtained XRPD pattern is different from 
those observed for CA·NaCl/NaBr or CA·NaBr·2H2O.  
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The interaction of cyanuric acid with potassium iodide led to the formation of 
CA∙KI∙H2O. Actually, it was the only case when it was possible to recrystallize 
the obtained ionic co-crystal and to solve its structure using single crystal data. 
It is a monoclinic crystal system. The coordination of K+ is similar to the one 
observed in CA∙KBr with the only difference that it interacts with four 
molecules of CA and the two missing coordinates are fulfilled by oxygens 
derived from water (fig. 3.2.3-9). 
 
Figure 3.2.3-9 CA∙KI∙H2O. Water molecules are marked in green for clarity.  
 
The crystal structure of CA∙RbI appeared to be isomorphous to the one of 





Figure 3.2.3-10 XRPD of CA∙RbI and CA∙KBr  
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3.2.4.1 Supporting Information 
Table 3.2.3-1 Structural data for ICCs solved from XRPD data. 
 NaBr·CA 
2H2O 















































a (Å) 8.52(1) 7.12(1) 8.58(1) 9.08(1) 7.69(1) 4.52(1) 7.57(1) 6.79(1) 
b (Å) 7.20(1) 8.22(1) 12.88(1) 12.84(1) 7.69(1) 21.46(1) 8.24(1) 21.48(1) 
c (Å) 7.86(1) 13.07(1) 6.80(1) 6.86(1) 6.43(1) 6.48(1) 13.83(1) 6.65(1) 
α (°) 101.51(1) 90.0 90.0 90.0 90.0 90.0 90.0 90.0 
β (°) 91.77(1) 90.0 90.0 90.0 90.0 106.68(1) 90.0 139.75(1) 
γ (°) 105.04(1) 90.0 90.0 90.0 120.0 90.0 90.0 90.0 
V (Å
3
) 455.5(1) 766.6(1) 752.6(1) 800.6(1) 329.9(1) 603.2(1) 864.5(1) 627.2(1) 
R_wp 4.94%* 5.78% 9.46% 7.62% 8.8% 8.89% 6.30% 6.65% 
*3-50 2-thetha flat stage 
 
 






Figure 3.2.3-12 CA·CsBr. 
 
 




Figure 3.2.3-4 CA·KBr. Some traces of KBr are present in the XRPD pattern. 
 
 












Figure 3.2.3-8 CA2·RbCl, Some traces of RbCl are present in the XRPD pattern. 
 




Figure 3.2.3-10 DSC trace for cyanuric acid. 
 
 





Figure 3.2.313 DSC trace for CA2·CsCl. 
 
 




Figure 3.2.3-14  DSC trace for CA·NaBr. 
 
 





Figure 3.2.314 DSC trace for CA·RbBr. 
 
 





Figure 3.2.3-18  DSC trace for CA·NaI. 
 
 





Figure 3.2.3-150  TGA trace for CA2·RbCl. 
 
 





Figure 3.2.3-17  TGA trace for CA·NaBr·2H2O. 
 
 





Figure 3.2.3-19   TGA trace for CA·KBr. 
 
 





Figure 3.2.3-21    TGA trace for CA·CsBr. 
 
 






The interaction of cyanuric acid with alkali halides resulted into formation of 
fourteen new ionic co-crystals. The ICCs were obtained mechanochemically – 
by grinding in the presence of a minimal quantity of a solvent. Such a synthetic 
technique represents a green chemistry approach. The structures of eleven of 
them were determined: ten were solved from XRPD patterns and one using 
single crystal data. The peculiarities of the crystal packing of ICCs depending on 
the nature of the ions were demonstrated. The solubility properties of CA∙NaCl 
were investigated. The co-crystal appeared to be much more soluble compared 




3.3. Mechanochemical preparation of molecular and ionic co-
crystals of the hormone melatonin 
3.3.1. Overview 
The search for new possible formulations of natural antioxidants and 
geroprotectors L-carnosine and melatonin aimed at optimizing physicochemical 
properties has become the main scope of my Master thesis.37 L-carnosine was 
co-crystallized with a number of organic acids which belong to the GRAS38 
(Generally Recognized As Safe) list.39 Melatonin, in turn, was co-crystallized 
with a number of molecular co-formers, but only two molecular co-crystals 
were obtained.37 Consequently, we decided to try and obtain ionic co-crystals 
upon co-crystallizing melatonin with pharmaceutically acceptable inorganic 
salts, namely NaCl, ZnCl2, CaCl2 and MgCl2. Melatonin is barely soluble in water 
and the idea was to test the possibility to enhance its solubility characteristics 
via co-crystallization with highly water soluble inorganic salts. However, only 
one ionic co-crystal Mel2·CaCl2·2H2O was obtained. It was structurally 
characterized using thermogravimetric and XRPD data. The solubility study 
showed significant improvement of solubility characteristics of the co-crystal 
compared to those of melatonin itself.  
 
3.3.2. Introduction 
Pharmaceutical co-crystals4, 40-43 are multicomponent crystalline materials 
composed of an Active Pharmaceutical Ingredient (API) and at least one co-
former, i.e. a benign molecule combined with the API in a specific 
stoichiometric ratio. To completely fulfil the requirements of co-crystals, both 
the API and the co-former(s) must be solid at ambient conditions.44 
74 
 
Pharmaceutical co-crystals have been attracting scientists as they can not only 
considerably diversify the solid forms of APIs, but also improve their 
physicochemical properties (solubility,45 dissolution rate,46, 47 bioavailability,48 
melting point,49 etc.). The wide range of possible co-formers provides 
numerous strategies to manipulate the physicochemical properties of interest. 
More recently the choice of co-formers has been amply expanded by the use of 
pharmaceutically acceptable inorganic salts, e.g. some alkali and alkaline earth 
halides, in the co-crystal formation. These so called ionic co-crystals (ICCs)1, 2 
provide alternative routes to modify the solid state properties of the API.9, 11 
Recently this type of co-crystals has been proven to be useful in the context of 
chiral resolution.50-52 In this paper we report the results of the investigation of 
the co-crystal landscape of the hormone melatonin.53 
Melatonin has been the subject of intense investigations, as witnessed by the 
number of scientific publications in the period 1985-2018 containing the word 
“melatonin” in their titles: 17 398 (of which more than 600 this year; source: 
Web of ScienceTM). A review article on the impact of melatonin in research has 
recently been published.54 To date, only one co-crystal of melatonin with 
pimelic acid was reported.55 This co-crystal showed a twofold increase in 
solubility characteristics and a 30% increase in the intrinsic dissolution rate 
compared to those of melatonin. 
Melatonin (N-acetyl-5-methoxy-tryptaminem, Fig. 3.3.2-1) is the pineal 
hormone produced from the essential amino acid tryptophan mainly during the 
night.56 It plays a vital role in the regulation of circadian and seasonal changes 
in various aspects of physiology and neuroendocrine function. In other words, 
it is responsible for the body internal timekeeping system and for the 
regulation of the sleep-wake cycle and seasonal adaptation. In addition to its 
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main functions, melatonin is also a powerful free-radical scavenger and wide-
spectrum antioxidant.53, 56, 57 
 
Figure 3.3.2-1 Melatonin. 
 
Melatonin plays an essential role in human healthy life and the shortage of this 
antioxidant may result into oxidative damage of DNA, lipids and proteins: 
potential risks are accelerated senescence and development of ageing-related 
diseases (e.g. coronary heart disease, cerebrovascular disease, cancer, arthritis, 
dementia, cataract, osteoporosis, type II diabetes, hypertension, Alzheimer's 
disease, Parkinson’s disease, etc.).57, 58  
Therefore, the increasing interest in the consumption of exogenous 
melatonin is not surprising. Generally, it is used to treat insomnia, jet lag, 
shift work disorder, circadian rhythm disorders in blind individuals, and 
benzodiazepine and nicotine withdrawal.59 According to the US Food and 
Drug Administration (FDA) melatonin is a dietary supplement.60 Its 
solubility in water is low;61, 62 this fact can limit its oral bioavailability in 
humans and, consequently, solubility enhancement would be highly 
desirable. To this end, we have explored co-crystal formation with a large 
number of potential co-formers. 
We have succeeded with the cyclic diamines piperazine (PIP) and 1,4-diaza-
bicyclooctane (DABCO) while CaCl2  was successful in yield a di-hydrated ICC. 
The co-crystallization of melatonin with CaCl2 is of particular interest since the 
organic salt belongs to the GRAS list.38 The preparation, isolation, structural 
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features and solubility profiles will be discussed in the following. The structures 
of the products mel2PIP and mel2CaCl22H2O were determined directly from 
powder diffraction data, while crystals suitable for single-crystal experiments 
were obtained for mel2DABCO. 
 
3.3.3. Experimental part 
Materials and instrumentation 
All reagents and solvents used in this work were purchased from Sigma-Aldrich 
and used without further purification. 
Solid State Synthesis 
Co-crystals of melatonin with DABCO, mel2DABCO, and piperazine, mel2pip, 
and the hydrated ionic co-crystal with CaCl2, mel2CaCl22H2O, were obtained by 
mechanochemistry: Melatonin (0.1 mmol) and the corresponding co-former 
(0.05 mmol) were kneaded for 30 minutes in a Retsch MM400 ball miller, 
operated at a frequency of 20 Hz, in the presence of a few drops of ethanol. 
Mel2DABCO crystals suitable for single crystal X-ray diffraction analysis were 
obtained by slow evaporation of a dichloromethane saturated solution of the 
kneading product. 
Slurry 
Mel2CaCl22H2O was also obtained by slurrying equimolar amounts of 
melatonin and CaCl2∙6H2O in ethanol for two days. 
X-ray powder diffraction measurements 
Room temperature X-ray powder diffraction (XRPD) patterns were collected on 
two different diffractometers: on a Bruker D2 phaser X-ray diffractometer in 
the 2θ range from 3° to 37° using a Cu-Kα (λ=1.54 Å) source equipped with a 
LinxEye detector, nickel filter and operated at 30 kV and 10 mA and on a 
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PANalytical X’Pert PRO automated diffractometer equipped with a X’Celerator 
detector in the 2θ range 3–50° (step size 0.011, time/step 50 s, VxA 40x40). 
Data analyses were carried out using the PANalytical X’Pert Highscore Plus 
program. The identity between the bulk material obtained via solution and 
solid-state processes was always verified by comparing calculated and 
observed powder diffraction patterns (see SI fig. 3.3.5-9-10). 
Structural Characterization from powder data 
Powder diffraction data were analysed with the software X’Pert HighScore Plus. 
15 peaks were chosen in the 2θ range 3-37, and unit cell parameters were 
found using DICVOL463 or DICVOL663 algorithms. The procedure for the 
structure solution of mel2CaCl22H2O is described here. This ICC is 
characterized by a monoclinic unit cell with a volume of 1501.51(1) Å3, 
compatible with the presence of four molecules of melatonin, two Ca2+, four Cl- 
anions and four water molecules. The structure was solved in the space group 
P21/c by simulated annealing, performed with EXPO2014
30 using one 
melatonin, one chloride, water and calcium moieties (the latter was found to 
be on a special position). Ten runs for simulated annealing trial were set, and a 
cooling rate (defined as the ratio Tn/Tn-1) of 0.95 was used. The best solutions 
were selected and used for Rietveld refinements, which was performed with 
the software TOPAS532. An overall thermal parameter was adopted for all 
atoms of melatonin. All hydrogen atoms were fixed in calculated positions. 
Structural data for all compounds investigated in this work are listed in Table 
3.3.3-1. 
 
Table 3.3.3-1 Structural data for melatonin co-crystals and ionic co-crystals. 
 mel2pip mel2DABCO mel2CaCl22H2O 
Formula C30H42N6O4 C32H44N6O4 C26H36N4O6CaCl2 





Monoclinic Monoclinic Monoclinic 
Space group P21/c P21/c P21/c 
Z, Z’ 2, 0.5 2, 0.5 2, 0.5 
a (Å) 17.051(6) 17.685(4) 18.965(4) 
b (Å) 9.831(3) 9.925(2) 8.9353(14) 
c (Å) 9.334(3) 9.2960(19) 8.9870(18) 
α (°) 90.0  90.0 90.0 
β (°) 105.099(17) 103.39(3) 99.634(17) 
γ (°) 90.0 90.0 90.0 
V (Å3) 1510.61(8) 1587.3 (6) 1501.50(5) 
R_wp 4.24 - 4.83 
d / mg.cm-3 - 1.207 - 
 / mm-1 - 0.081 - 
Measd reflns - 22619 - 
Indep reflns - 3453 - 
Reflns (I > 
2σ(I)) 
- 2689 - 
Rint - 0.034 - 
R[F2 > 2σ(F2)] - 0.09 - 
wR(F2) - 0.171 - 
 
Single Crystal X-ray Diffraction 
Single crystal X-ray data for mel2DABCO were collected at RT and at 150K 
on a Bruker D8 and an X8 Apex II diffractometers, respectively, both 
equipped with MoKα X-ray source and graphite monochromator. Multi-
scan absorption correction (SADABS) was applied. Data collection and 
refinement details are listed in Table 1. All non-hydrogen atoms were 
refined anisotropically. The DABCO molecule in mel2·DABCO is disordered 
around a crystallographic inversion centre. HCH and HNH atoms were 
added in calculated positions and refined riding on their respective 
carbon atoms. The structure was solved by the Intrinsic Phasing methods and 
refined by least squares methods again F2 using SHELXT-201464 and SHELXL-
201465. The program Platon66 was used to calculate hydrogen bond 
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distances. Schakal35 and Mercury 3.1036 were used for molecular 
graphics.  
Differential Scanning Calorimetry (DSC) 
DSC measurements were performed for melatonin and its co-crystals with a 
Perkin–Elmer Diamond. Samples (3–5 mg) were placed in hermetic aluminium 
pans. Heating was carried out at 5°C min-1 for all samples. 
Thermogravimetric Analysis (TGA) 
TGA measurements of melatonin and its co-crystals were performed using a 
Perkin-Elmer TGA7 in the temperature range 30-400 °C under an N2 gas flow, at 
a heating rate of 5 °C min-1. 
Solubility test for mel2CaCl22H2O. 
A small amount of mel2CaCl22H2O was weighed and portions of it were added 
to a test tube containing 1mL of water at room temperature and shaken until 
the solid was completely dissolved. The procedure was repeated until no more 
mel2CaCl22H2O could be dissolved. The remaining co-crystal was weighed and 
the difference with the initial quantity calculated as the amount of the co-
crystal dissolved. The experiment was repeated 3 times and the average value 
was used. 
 
3.3.4. Results and Discussion 
Co-crystals of melatonin with piperazine and DABCO 
Despite the wide interest in melatonin, only one example of melatonin 
co-crystal, melatonin∙pimelic acid, has recently been reported in the 
literature.55 Co-crystallization of melatonin was attempted with a number 
of co-formers, containing different functional groups (see Table SI 3.3.5-
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1-4), by applying a variety of methods such crystallization from solution, 
grinding, kneading and slurry, all in various stoichiometric ratios. In no 
instance co-crystallization with melatonin was observed, and the 
products invariably resulted in a mixture of the starting materials. 
Successful results were obtained only when we used diamine bases as co-
formers; in this way the base can act as a hydrogen bonding bridge 
between two melatonin molecules, thus disrupting the dimer present in 
pure melatonin, which is further stabilized by four hydrogen bonding 
interactions with amido oxygen of four neighbouring melatonin 
molecules (see Fig. 3.34-1). 
a) 
b) 
Figure 3.3.4-1   HB-pattern in crystalline melatonin (MELATN01). 
The main packing motif is the hydrogen bonded “dimer” formed by two melatonin 
molecules referred by an inversion centre (C atoms in orange) (a). The dimer is then 
interacting via further hydrogen bonds with four melatonin molecules, thus forming a thick, 
infinite 2D-layer (b) extending in the bc-plane. 
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The diamine bases piperazine and DABCO (1,4-diazabyclooctane) were selected 
to react with melatonin; DABCO does not belong to the GRAS family, but was 
chosen because of its similarity, both in shape and functions, with piperazine. 
We were able to obtain the two co-crystals mel2∙DABCO and mel2∙pip by ball-
milling melatonin with DABCO or piperazine in a 2:1 ratio, in the presence of a 
drop of ethanol. In the case of DABCO single crystals were obtained from 
solution reaction in dichloromethane, and full structural characterization of 
mel2∙DABCO was possible via single crystal X-ray diffraction.  
Fig. 3.3.4-1a shows how the N-H∙∙∙Oamido hydrogen bonds present in the pure 
melatonin dimer are replaced in mel2∙DABCO by Nbase···(H)Nmelatonin hydrogen 
bonds.  
Attempts at obtaining single crystals of mel2∙pip, following the same procedure, 
were unsuccessful. Given the strong similarity of their X-ray powder patterns 
(see Fig. SI 3.3.5-12), and the similarity in shape and hydrogen bonding 
propensity of piperazine and DABCO, we assumed that the two co-crystalline 
materials were isomorphous; the structure of mel2·pip was thus solved from 
powder data (see Fig. 3.3.4-2b), using as a model the structure of mel2·DABCO. 
The whole crystal in both mel2∙DABCO and mel2∙pip can be described as formed 
by alternating layers of melatonin and piperazine or DABCO molecules, as it is 







Figure 3.3.4-2 The DABCO (a) and piperazine (b) molecules bridge pairs of melatonin 
molecules via hydrogen bonds of the N···(H)Nmelatonin type. The whole crystal can be 
described as alternating layers of melatonin and piperazine or DABCO molecules extending 
parallel to the b-axis, as it is shown here; (c) for crystalline mel2∙pip (hydrogen atoms 
omitted for clarity). Orange circles in (d) indicate DABCO nitrogen atoms. 
 
Hydrated ionic co-crystal of melatonin with CaCl2 
Ionic co-crystals (ICCs) are currently attracting the interest of scientists working 
with pharmaceutical compounds, as they make possible to build crystalline 
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materials comprising  charged ions, i.e. Coulombic interactions, and 
unmodified, neutral APIs.2 This is particularly relevant for systems that do not 
possess hydrogen bonding donors or acceptor to be used for the construction 
of molecular co-crystals. By reacting equimolar quantities of melatonin and 
CaCl2∙6H2O in a slurry experiment with ethanol, we were able to obtain the 
dihydrated ionic co-crystal mel2∙CaCl2∙2H2O. Figure 3.3.4-3 shows the first 
coordination sphere of the calcium cation, which lies on a crystallographic 
inversion centre: two water molecules, two Oamido atoms belonging to 
melatonin and two chloride ions constitute the vertices of an octahedron; 
infinite layers of octahedra extend parallel to the crystallographic bc-plane (see 
fig. 3.3.4-4). Charge-assisted hydrogen bonding interactions of the N(H)∙∙∙Cl- 
type [N(H)∙∙∙Cl- 3.45(1) Å] are present between the chloride anions and the NH 
groups on melatonin. As a result, charged species and hydrogen bond acceptor 




Figure 3.3.4-3 The coordination of melatonin, water molecules (blue) and chlorides to 
Ca2+.The NH groups indicated by the arrow are hydrogen bonded to chloride ions belonging 






Figure 3.3.4-4 The crystal packing of mel2∙CaCl2∙2H2O.Top: view along the c-axis; bottom: 
layer, view along the a-axis. 
 
In our recent paper it was shown that the co-crystallization of cyanuric 
acid with sodium chloride resulted in a significant improvement of 
solubility characteristics of the organic molecule.12 Thus, in view of the 
interest in increasing the solubility of melatonin in water the 















































Figure 3.3.4-5 Comparison of the solubility in water at 293 K for melatonin61 and the ionic 
co-crystal mel2∙CaCl2∙2H2O, in g*L
-1 (left) and in mol*L-1 (right). 
 
The thermodynamic solubility of mel2∙CaCl2∙2H2O showed an impressive 
difference, with an increase of about 8.5 times with respect to the pure organic 
compound (0.0744(1) versus 0.0086 mol*L-1) (fig. 3.3.4-5). In order to 
investigate the possibility of existence of the obtained ICC as an anhydrous 
product, variable temperature experiments have been performed. However, 
the only change one could observe was amorphization of the product at the 




3.3.5. Supporting information 
 
 
Figure 3.3.5-1 TGA of melatonin. 
 





Figure 3.3.5-3 TGA of mel2DABCO. 
 




Figure 3.3.5-5 TGA of mel2pip. 
 
 




Figure 3.3.5-7 TGA of mel2CaCl22H2O. 
 
 
Figure 3.3.5-8 DSC of mel2CaCl22H2O.
90 
 
XRPD: comparison between reagents and products 
 








2 / deg  
Figure 3.3.5-9 XRPD comparison between mel2·DABCO and starting materials.
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Figure 3.3.5-11 Comparison between the XRPD patterns of the mel2∙pip and mel2∙DABCO 
co-crystals. 
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Rietveld refinements  
Experimental (blue curve), calculated (red curve), and difference (grey curve) powder 
patterns. Peak positions are marked in blue. 
 
Figure 3.3.5-13 Rietveld refinement of mel2∙CaCl2∙2H2O. 
 
 
Figure 3.3.5-14 Rietveld refinement of mel2·pip. 
Tables of co-formers tested. 
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Table 3.3.5-1 Organic acids. 
# Co-former Method Results 
1 Nicotinic acid Kneading with EtOH ✘ 
2 Fumaric acid Kneading with EtOH ✘ 
3 Isophthalic acid Kneading with EtOH ✘ 
4 4-aminosalicylic acid Kneading with EtOH ✘ 
5 Succinic acid 1:2 Kneading with EtOH ✘ 
6 Glutaric acid 1:2 Kneading with EtOH ✘ 
7 Ascorbic acid Kneading with EtOH ✘ 
8 Barbituric acid Kneading with EtOH ✘ 
9 Nalidixic acid Kneading with EtOH ✘ 
 
Table 3.3.5-2 Amino acids. 
# Co-former Method Results 
1 L-tryptophan Kneading with EtOH ✘ 
2 L-Glutamic acid Kneading with EtOH ✘ 
3 L-Glutamine Kneading with EtOH ✘ 
4 L-Histidine Kneading with EtOH ✘ 
5 L-aspartic acid Kneading with EtOH ✘ 
 
Table 3.3.5-3 Inorganic salts. 





Kneading with EtOH 
Slurry in EtOH 
Evaporation from EtOH 








Kneading with EtOH 
Slurry in EtOH 




3 KBr Kneading with EtOH ✘ 
4 NaCl Kneading with EtOH ✘ 




Kneading with EtOH 
Slurry in EtOH 




7 SrCl2·6H2O Kneading with EtOH ✘ 
8 NaBr Kneading with EtOH ✘ 
9 
ZnCl2 
Kneading with EtOH 
Slurry in EtOH 
Evaporation from EtOH 




10 AgNO3 Kneading with EtOH ✘ 
11 Cu(NO3)2·3H2O Kneading with EtOH ✘ 
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Table 3.3.5-4 Phenols. 
# Co-former Method Results 
1 Thymol 
 
Kneading with EtOH 







Slurry in the excess of eugenol 








Slurry in the excess of carvacrol 





Table 3.3.5-5 Nitrogen containing compounds. 
# Co-former Method Results 









Kneading with EtOH 
Evaporation from EtOH 




4 DABCO (triethylenediamine) 
 
 
Kneading with EtOH 
Evaporation from ethanol 







Kneading with EtOH 
Slurry in EtOH 
Evaporation from EtOH 
✘ 
6 e-Caprolactam Kneading with EtOH ✘ 
7 Caffeine anhydrous Kneading with EtOH ✘ 
8 4,4'-trimethylenedipiperidine Kneading with EtOH ✘ 
9 Hexamine 
 
Kneading with EtOH 
Evaporation from EtOH 
✘ 
✘ 
10 Carbamazepine Kneading with EtOH ✘ 
11 Pyrazine 
 
Kneading with EtOH 
Slurry in EtOH 
✘ 
✘ 
12 Quinuclidine Kneading with EtOH ✘ 







Kneading with EtOH 
Slurry in EtOH 
Evaporation from water/ethanol mixtures 
Crystallization from melt 






15 Urea Kneading with EtOH ✘ 
16 4-aminopyridine Kneading with EtOH ✘ 
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Table 3.3.5-6 Various. 




Slurry in the excess of dioxane 
✘ 
✘ 




In this chapter the results of a systematic exploration of the possibility of 
preparing co-crystals of melatonin with a number of co-formers have been 
reported. Two molecular co-crystals and one ionic co-crystal of melatonin have 
been obtained. The structures of mel2pip and mel2∙CaCl2∙2H2O co-crystals were 
established by X-ray powder diffraction. The latter showed an 8-fold higher 
thermodynamic solubility characteristics compared to those of melatonin.  
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3.4. Exploring chiral resolution in the solid-state via ionic co-
crystal formation. 
The idea developed in this part of the research combines the issue of chirality 
with that of ionic co-crystal formation. Initially, the scope of this research was 
more general: to apply the formation of both molecular and ionic co-crystals as 
a tool to either separate a particular enantiomer from a racemic mixture or to 
prevent its possible transformation into a different form. However, after some 
preliminary results on the co-crystallization of both enantiopure and racemic 
histidine with lithium halides were obtained50, we decided to focus all our 
efforts on the ICCs. Li+ cations selectively link to molecules of the same 
chirality, forming enantiopure chains, resulting in some of the cases in a chiral 
resolution process in the solid state via conglomerate formation. The co-
crystallization of the investigated amino acid with calcium halides did not show 
any effect on the chirality of the obtained ionic co-crystals.51 Taking into 
account the obtained results, it was speculated that one possible reason for 
chiral preference in ICCs formed by DL-histidine and lithium halides could be 
the nature of the cation which favours the coordination of molecules of the 
same handedness. We decided to put this hypothesis to test by attempting the 
co-crystallization of another amino acid – DL-proline with lithium halides.52 The 
obtained results appeared to be quite similar with those obtained for the co-
crystallization of histidine with lithium halides: once again the homochiral 
preference of lithium cations was observed in all the ICCs. In order to 
understand whether the phenomenon of lithium homochiral preference could 
be explained by a particular phenomenon of lithium cations per se or by the 
tetrahedral geometry around the lithium cations that could favour the 
coordination of molecules of the same handedness, it was decided to perform 
the complexation with a different metal cation favouring a tetrahedral 
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coordination. This time an antiepileptic drug – levetiracetam (enantiopure S-
etiracetam) and its racemic intermediate RS-etiracetam was co-crystallized 
with ZnCl2,
70 as zinc is known to favour tetrahedral coordination. In agreement 
with our working hypothesis, the complexation of the racemic etiracetam to 




3.4.1. Ionic Co-crystals of Racemic and Enantiopure Histidine: An 
Intriguing Case of Homochiral Preference 
The investigation of the peculiarities of co-crystallization of chiral compounds 
was started with the amino acid histidine and alkali chlorides and bromides.50 
The grinding with a drop of solvent (kneading18) was chosen for the preliminary 
screening. The obtained results showed that only the co-crystallization of 
lithium chloride and lithium bromide led to the formation of new phases. 
Consequently, it was decided to concentrate our efforts on the interaction of L- 
and DL-histidine with lithium halides. The obtained results appeared to be 
quite interesting. As it could be expected, lithium cations had a tetrahedral 
coordination. It was formed by three different molecules of histidine and a 
molecule of water. However, the most intriguing aspect was the 
enantioselective complexation of the racemic amino acid to lithium cations: 
each Li+ was selectively coordinated by the amino acids of the same 
handedness forming the infinite chains of L-histidine·Li+ and D-histidine·Li+. 
Furthermore, it was found that the enantiopure chains observed in both 
racemic and conglomerate crystals are of the same type observed in the ICCs 
prepared with enantiopure L-Histidine. And as it was found out later, this 
peculiar coordinative feature could not only result into formation of these 
enantiopure chains, but also lead to the spontaneous chiral resolution with the 
formation of conglomerates. 
A detailed report on the co-crystallization of enantiopure and racemic histidine 








3.4.2. Ionic Co-crystals of Racemic and Enantiopure Histidine: An 
Intriguing Case of Homochiral Preference 
The promising results of the co-crystallization of the racemic histidine with 
lithium halides encouraged us to further investigate the influence of the 
complexation of D- and L-histidine molecules to metal cations. Since histidine 
did not form ICCs with all the alkali metals but lithium we decided to co-
crystallize it with calcium halides. The interaction of both racemic and 
enantiopure histidine resulted into formation of the corresponding ionic co-
crystals of the general formula (L-His)2∙CaX2∙nH2O (X= Cl and Br n=3, X= I n=4). 
However, this time the complexation of the racemic histidine to calcium cations 
had no influence on the chirality: the obtained ICCs accommodated molecules 
of both chiralities in the coordination sphere of the Ca2+ cations. Intrinsic 
dissolution rate measurements show that the histidine-CaCl2 co-crystals have a 
much higher IDR with respect to both enantiopure and racemic histidine solids. 
A detailed report on the co-crystallization of enantiopure and racemic histidine 













3.4.3. Ionic Co-crystal Formation as a Path Towards Chiral 
Resolution in the Solid State 
As it was already mentioned in chapter 3.3.1, the co-crystallization of DL-
histidine and lithium halides led to the formation of racemic co-crystals. In 
these co-crystals lithium cation exhibited a clear-cut homochiral preference: Li+ 
cations were selectively bound to molecules of single handedness thus forming 
infinite “enantiopure” (L-His·Li)n
n+ / (D-His·Li)n
n+ chains. The co-crystallization 
with lithium iodide proceeded a step further along the path towards chiral 
separation, and the conglomerate of D-His·LiI·H2O and L-His·LiI·H2O was 
obtained.50 
A different behaviour was observed for calcium halides: racemic ICCs with DL-
histidine were obtained,51 in which each calcium cation formed an octahedral 
coordination with histidine molecules of both chiralities. 
Taking into account the information given above, it was speculated that the 
lithium cation tetrahedral coordination could be the key factor in the lithium 
homochiral preference. In order to test this assumption, we decided to co-
crystallize lithium halides with another amino acid proline. One more important 
aspect we planned to investigate was the possible role of the size of the anion 
in the chiral resolution since it took place only in the co-crystallization of DL-
histidine with lithium iodide.50 
This time the co-crystallization of both enantiopure and racemic proline with 
lithium halides was investigated more detailed: different solvents, 
stoichiometric ratios and synthetic techniques were used. Since the majority of 
ICCs were obtained in the form of hydrates, the thermal behaviour of the 













3.4.4. Solid-state chiral resolution mediated by stoichiometry: 
crystallizing etiracetam with ZnCl2 
Based on the information obtained by the co-crystallization of amino acids 
histidine and proline with lithium and calcium halides it was argued whether 
the phenomenon of lithium homochiral preference could be explained by a 
particular phenomenon of lithium cations per se or by the tetrahedral 
geometry around them that could favour the coordination of molecules of the 
same handedness. In order to find it out it was decided to perform the 
complexation with a different metal cation favouring a tetrahedral 
coordination. This time zinc in the form of their ZnCl2 salt was used, as zinc is 
known to favour tetrahedral coordination. Instead of using an amino acid we 
decided to try and to co-crystallize ZnCl2 with an antiepileptic drug – 
levetiracetam (enantiopure S-etiracetam) and its racemic intermediate – RS-
etiracetam. 
In agreement with our working hypothesis, the complexation of the racemic 
etiracetam to zinc cations appeared to be enantioselective. Moreover, in this 
particular case it was possible to use different amounts of ZnCl2 to reversibly 













3.4.4.1 Supplementary Information 
The link to the supporting information is reported here: 
http://www.rsc.org/suppdata/c8/cc/c8cc06199h/c8cc06199h1.pdf 
1. Experimental Procedures 
S-2-(2-oxopyrrolidin-1‐yl)butanamide (Levetiracetam, S-ETI) was purchased from 
Xiamen Top Health Biochem Tech. Co., Ltd. (RS)-2-(2-oxopyrrolidin‐1-yl)butanamide 
(Etiracetam, RS-ETI) was prepared by racemization of S‐2-(2-oxopyrrolidin‐1‐
yl)butanamide. 10g of S‐2‐(2‐oxopyrrolidin‐1‐yl)butanamide together with catalytic 
amount (0.05 eq.) of MeONa were added to 10 mL of MeOH. The solution was kept 
at reflux under continuous stirring for 24h, and then cooled to room temperature. The 
compound crystallizes spontaneously. After filtration, the compound was washed 
twice with MeOH. The recovered compound was used as such. All the other reagents 
were purchased from Sigma and used without further purification. 
 
1.1 Solution Synthesis. Equimolar quantities of the starting materials (S-ETI:ZnCl2 
1:1 and RS-etiracetam:ZnCl2 2:1) were dissolved in 2 mL of ethanol at room 
temperature. Slow evaporation of the solvent at room temperature resulted in the 
formation of an oil-like substance, which after several days precipitated as complexes 
S-ETI·ZnCl2 and RS-ETI2·ZnCl2.  
 
1.2 Solid-state synthesis. Pure complexes of S-ETI·ZnCl2 and RS-ETI2·ZnCl2 were 
obtained mechanochemically by ball-milling the stoichiometric ratios of the starting 
materials in an agate jar for 60 min in a Retsch MM200 ball miller, operated at a 
frequency of 25 Hz, with the addition of a drop of ethanol.  
 
1.3 Slurry synthesis. S-ETI·ZnCl2 and RS-ETI2·ZnCl2 were also obtained by 
slurrying for 2 days, in the minimum quantity of ethanol, methanol or water, the 




1.4 Thermogravimetric analysis. TG analyses for S-ETI·ZnCl2 and RS-ETI2·ZnCl2 
were performed with a TGA/SDTA 851 Mettler Toledo instrument. Samples were 
placed in open aluminium oxide crucibles annealed at 1100 °C. The heating rate was 
2 °C/min over the range 25-350 °C. All experiments were carried out under nitrogen 
atmosphere. 
TGA measurements for RS-ETI, S-ETI and R-ETI·ZnCl2 / S-ETI·ZnCl2 conglomerates 
were performed with a PerkinElmer TGA7 in the temperature range 40-500 ºC under 
N2 gas flow at a heating rate of 5.00 ºC min
-1. 
 
1.5 Differential Scanning Calorimetry. DSC measurements for S-ETI·ZnCl2 and 
RS-ETI2·ZnCl2 were performed on a TA DSC2500 with T0 technology, after 
calibration with indium. Samples were placed in aluminium perforated T0 pans, under 
continuous nitrogen flow. A heating ramp at 5°C/min from 30°C to 250°C was applied 
for all samples. 
DSC thermograms for RS-ETI, S-ETI and R-ETI·ZnCl2 / S-ETI·ZnCl2 conglomerates 
were recorded using a Perkin-Elmer Diamond. The samples (1-3 mg range), obtained 
through kneading were placed in open or Al-pans. All measurements were conducted 
at a heating rate of 5 or 10ºC min-1. 
 
1.6 Ternary Phase Diagram. The ternary phase diagram (TPD) was constructed by 
slurrying RS-ETI and ZnCl2 in ethanol, varying the molar ratio of the starting materials 
from 0 to 1. Experiments were carried out in a number of 2 mL sealed vials, and the 
suspensions were stirred at constant temperature (25 °C) over 48 h. Seeding with all 
possible solid-state forms was performed to make sure that the system reached 
thermodynamic equilibrium. Afterwards the samples were filtered by sand core 
funnel. The solid phases were characterized by XRPD. Concentration of zinc in the 
supernatant solution could not be determined via HPLC, due to transparency to UV 
radiation. Hence, to determine the equilibrium compositions, necessary for the 
determination of the solubility lines, each experimental condition described above 
was repeated, but this time the samples were not filtered; small portions of solvent 
were added to the stirring mixtures every 30 minutes, until complete dissolution of the 
suspended solid was observed. This allowed the construction of the solubility line in 
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Fig. ESI-1. TPD of a generic co-crystal AB and a solvent; L is the liquid phase. Green dots: 
experimental ratios of the A and B components slurried in a fixed quantity of the solvent. Red broken 
line: solubility curve; this was determined by addition of small quantities of solvent to the known 
mixtures of the starting materials: in this figure the 9:1 of A:B ratio has been chosen as an example. 
The addition of solvent to the given suspension moves the composition towards the solvent vertex of 




2. X-ray diffraction analysis. 
2.1 Single Crystal X-ray Diffraction. Single Crystal data were collected at room 
temperature with an Oxford Diffraction X´Calibur equipped with a graphite 
monochromator and a CCD detector. Mo-Kα radiation ( = 0.71073 Å) was used. Unit 
cell parameters for both complexes discussed herein are reported in Table ESI-1. 
The structure was solved by the Intrinsic Phasing methods and refined by least 
squares methods again F2 using SHELXT-201464 and SHELXL-201865 with OLEX 2 
interface.71 Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were 
added in calculated positions and refined riding on their respective carbon or nitrogen 
atoms. The software Mercury 3.10.172 was used for graphical representations and for 
powder patterns simulation on the basis of single crystal data.  
Table ESI-1. Crystal data and details of measurements for S-ETI·ZnCl2 and RS-ETI2·ZnCl2. 
 S-ETI·ZnCl2 RS-Eti2·ZnCl2 
Chemical formula C16H28Cl4N4O4Zn2  C16H28Cl2N4O4Zn  
Mr, g*mol
-1 612.96 476.69 
T / K 293 (2) 293 (2) 
Morphology, colour Block, colourless Block, colourless 
Crystal system Monoclinic Monoclinic 
Space group P21 C2/c 
a / Å 6.3692 (3) 17.6678 (6) 
b / Å 11.6771 (4) 6.9371 (2) 
c / Å 17.1077 (6) 18.0628 (8) 
α / ° 90 90 
 / ° 98.496 (4) 91.515 (3) 
γ / ° 90 90 
V / Å3 1258.40 (9) 2213.06 (14) 
Z 2 4 
d / mg.cm-3 1.618 1.431 
 / mm-1 2.36 1.38 
Measd reflns 6011 4853 
Indep reflns 4612 2561 
Reflns with I > 2σ(I) 4031 2118 
Rint 0.024 0.027 
R[F2 > 2σ(F2)] 0.0435 0.0425 
wR(F2) 0.092 0.098 
Crystal data can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
https://www.ccdc.cam.ac.uk and have been allocated the accession numbers CCDC 1857803 




2.2 X-ray Diffraction from Powder. For phase identification purposes X-ray powder 
diffraction (XRPD) patterns were collected on a PANalytical X´Pert Pro Automated 
diffractometer equipped with an X´celerator detector in Bragg-Brentano geometry, 
using Cu-Kα radiation (=1.5418 Å) without monochromator in 3-50° 2θ range (step 
size 0.033º; time/step: 20 s; Soller slit 0,04 rad, antiscatter slit: ½, divergence slit: ¼ ; 
40 mA*40kV).  
 
2.3 Variable temperature X-ray diffraction. 
VT-XRPD diffractograms were collected in the 5-50° 2θ range on a PANalytical 
X'Pert PRO automated diffractometer, equipped with an X'Celerator detector and an 
Anton Paar TTK 450 system for measurements at controlled temperature. Data were 
collected in open air in Bragg-Brentano geometry, using Cu-Kα radiation without a 





3. Experimental results 
3.1 RS-Etiracetam and S-Etiracetam. 
 
Fig. ESI-2. DSC trace for RS-ETI. 
 




Fig. ESI-3. DSC trace for S-ETI. 
 


















Fig. ESI-5. Comparison between the experimental (crystallization from solution) and calculated XRPD 
patterns for RS-ETI2·ZnCl2. 
 
The TGA shows a degradation process starting at 200°C, with DSC showing a single 
melting process at 132°C (onset), ca. 40°C lower than the one observed for S-
ETI·ZnCl2 (see below). VT-XRPD confirms (i) the presence of only one form and (ii) 
the melting of that form at higher temperatures. Recrystallization from the melt is not 
observed.  
 
Fig. ESI-6. DSC trace of RS-ETI2·ZnCl2. 
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Peak temperature: 137.19 °C
Enthalpy (normalized): 110.59 J/g






Fig. ESI-7.: TGA of RS-ETI2·ZnCl2. 
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Fig. ESI-9.: S-ETI·ZnCl2. Hydrogen bonds between the chloride anions and the hydrogen atoms of the 
amido groups that hold together the zig-zag chains formed by ZnCl2 units bridged by S-etiracetam 
molecules. 









Fig. ESI-10. Comparison between the experimental (crystallization from solution) and calculated 




The TGA trace shows a degradation process starting at 220°C. A small initial mass 
loss is likely due to removal of residual solvent adsorbed on the surface of the 
sample. A similar observation can be made on the basis of the DSC trace, which 
shows an initial endotherm, which can easily be attributed to evaporation of residual 
solvent; at 176°C (onset) melting is observed. VT-XRPD confirms that only one form 
is present and melting of that form occurs above 180°C. Recrystallization from the 
melt is not observed.  
 
 
Fig. ESI-11. DSC thermogram of S-ETI·ZnCl2. 
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Peak temperature: 184.27 °C
Enthalpy (normalized): 76.500 J/g




Fig. ESI-12. TGA analysis of S-ETI·ZnCl2. 
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3.4 R-ETI·ZnCl2 / S-ETI·ZnCl2 conglomerate 
DSC analysis shows a single endothermic event, attributable to melting, at 156.64°C 
(onset), that is approximately 20 ° lower than the 176°C observed for the single 
enantiomer (Fig. ESI-11), as it can be expected for a conglomerate.73 
 
Fig. ESI-14. DSC trace for the R-ETI·ZnCl2 / S-ETI·ZnCl2 conglomerates. 
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Fig. ESI-15. VT-XRPD for the R-ETI·ZnCl2 / S-ETI·ZnCl2 conglomerate. Some traces of RS-
ETI2·ZnCl2 are present in the sample (the corresponding peaks are marked with asterisks). Upon 
reaching 145 °C the peaks of the racemic complex are not observed any longer in the diffractograms, 
whereas the conglomerates are still stable.  
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4. TPD for the RS-ETI:ZnCl2:ethanol system. 
To construct a TPD for the RS-ETI:ZnCl2 system a series of physical mixtures of 
starting materials (200 mg of total weight) were prepared (see table ESI-2). To the 
obtained mixtures 0.35 mL of ethanol were added and slurry experiments performed 
at 25°C for 48h. The samples with the suspensions were seeded with both starting 
materials and with RS-ETI2·ZnCl2. Seeding material was prepared by kneading with 
ethanol (see synthesis). 
 
Table ESI-2. Initial Experimental Data for System of RS-ETI:ZnCl2:EtOH at 298 K. 200 mg of 






Initial components Initial components 
(mol %) 
















90:10 182.52 17.48 0.35 0.117 0.013 0.870 RS-ETI+ RS-ETI2·ZnCl2 
80:20 164.55 35.45 0.35 0.105 0.026 0.868 RS-ETI+ RS-ETI2·ZnCl2 
70:30 146.06 53.94 0.35 0.093 0.040 0.867 RS-ETI2·ZnCl2 
60:40 127.03 72.97 0.35 0.081 0.054 0.865 RS-ETI2·ZnCl2 





0.35 0.055 0.083 0.861 RS-ETI2·ZnCl2 + 
R-ETI·ZnCl2/S-ETI·ZnCl2 
30:70 66.43 133.57 0.35 0.042 0.098 0.860 Dissolved 
20:80 44.98 155.02 0.35 0.028 0.114 0.858 Dissolved 






Taking into account the fact that the given quantity of starting materials completely 
dissolved in all the cases where the excess of ZnCl2 was employed, the experiment 
was repeated using 500 mg of total weight and 0.3 mL of EtOH (see table ESI-3). 
 
Table ESI-3. Initial Experimental Data for System of RS-ETI:ZnCl2:EtOH at 298 K. 500 mg of total 






Initial components Initial components 
(mol %) 
















90:10 456.31 43.69 0.3 0.314 0.035 0.652 RS-ETI2·ZnCl2 + RS-ETI 
80:20 411.38 88.62 0.3 0.281 0.07 0.648 RS-ETI2·ZnCl2 + RS-ETI 











0.3 0.181 0.181 0.638 RS-ETI2·ZnCl2  + 
R-ETI·ZnCl2/S-ETI·ZnCl2 
40:60 218.09 281.91 0.3 0.146 0.219 0.635 R-ETI·ZnCl2/S-ETI·ZnCl2 
30:70 166.07 333.93 0.3 0.111 0.258 0.631 R-ETI·ZnCl2/S-ETI·ZnCl2 
20:80 112.44 387.56 0.3 0.074 0.298 0.628 R-ETI·ZnCl2/S-ETI·ZnCl2 
10:90 57.11 442.89 0.3 0.038 0.338 0.624 Too little quantity of 






The solubility curve was determined by adding small portions of ethanol to the stirring 
mixtures every 30 minutes, until the suspended solids were completely dissolved 
(see table ESI-4). 
 































100:0 0.3 3.95 500.00 0 4.25 0.042 0.000 0.958 
90:10 0.3 2.95 456.31 43.69 3.25 0.049 0.005 0.946 
80:20 0.3 3.55 411.38 88.62 3.85 0.038 0.009 0.953 
70:30 0.3 3.75 365.15 134.85 4.05 0.032 0.014 0.955 
60:40 0.3 3.95 317.56 182.44 4.25 0.026 0.018 0.956 
50:50 0.3 2.3 268.57 231.43 2.6 0.035 0.035 0.929 
40:60 0.3 1.2 218.09 281.91 1.5 0.047 0.071 0.882 
30:70 0.3 0.7 166.07 333.93 1.0 0.051 0.119 0.830 
20:80 0.3 0.5 112.44 387.56 0.8 0.059 0.235 0.707 
10:90 0.3 0.1 57.11 442.89 0.4 0.035 0.311 0.655 









Fig. ESI-16. Complete ternary phase diagram for RS-ETI:ZnCl2:EtOH at 298K (mol%). RS 
corresponds to R- and S-etiracetam correspondingly. x corresponds to the molecular ratio of 
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The aim of this project was to synthesize new multicomponent materials with 
improved physicochemical properties. The research activity was mainly 
dedicated to the investigations of solid solutions formed by organic molecules 
and of molecular and ionic co-crystals. The whole project can be subdivided in 
three main directions: 
1. Investigation of solid solutions consisting of organic molecules. 
2. Co-crystallization as a tool to modify physicochemical properties of 
interest. 
3. The effect of co-crystallization on chirality and its possible application for 
chiral resolution.  
 
4.1. Investigation of solid solutions consisting of organic 
molecules 
The first part of my PhD thesis was dedicated to the investigation of the 
crystalline solid solutions or organic alloys formed by barbituric and 
thiobarbituric acids. Initially, a 1 to 1 molecular co-crystal of these acids was 
obtained. The variation of the stoichiometric ratios of the starting materials 
resulted in the formation of new crystalline materials – solid solutions 
(BAxTBA1-x, x < 0.8). Thus, barbituric and thiobarbituric acids were found to be 
mutually miscible. All these mixed crystals were isomorphous with those of the 
parent components and were characterized by a structural disorder of carbonyl 
and thiocarbonyl groups that permitted the variation of the ratios of their 
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components. Generally, the BA:TBA solid system was found to be an intriguing 
system: the crystal packing of the obtained co-crystal was more favoured with 
respect to the parent homo-molecular crystalline materials. DSC traces of the 
BAxTBA1-x solid solutions with an excess of thiobarbituric acid showed that the 
obtained solids were not stable upon heating: the melting of BA and TBA 
followed by recrystallization to the BA·TBA co-crystal was observed. Moreover, 
the melting point of the BA·TBA co-crystal was found to be higher than those of 
both barbituric and thiobarbituric acids. Therefore, it was concluded that the 
co-crystal was more thermally stable compared to the parent components. As a 
matter of fact, this phenomenon is not common since typically the co-crystals’ 
melting points are either in between or lower than those of the starting 
materials. 
 
4.2. Co-crystallization as a tool to modify physicochemical 
properties of interest. 
This part of my research was dedicated to the synthesis and characterization of 
molecular and ionic co-crystals. The investigation began with the co-
crystallization of cyanuric acid with alkali metal halides. The kneading of 
equimolar quantities of cyanuric acid with the majority of the tested inorganic 
salts resulted into formation of ionic co-crystals. The structures of the obtained 
crystalline solids were solved using XRPD data. Almost all the obtained ionic co-
crystals are anhydrous. The co-crystallization of cyanuric acid with sodium 
chloride resulted in the formation of CA·NaCl. In view of the interest in 
increasing the solubility of cyanuric acid in water this co-crystal was chosen to 
test both the intrinsic dissolution rate (the rate at which the compound is 
released from its crystal lattice into solution) and the thermodynamic solubility. 
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The latter showed a dramatic difference: it was possible to dissolve about 20 
times more cyanuric acid in the form of CA·NaCl with respect to the pure 
organic compound. The positive effect on the intrinsic dissolution rate of the 
ICC compared to cyanuric acid itself was also detected though it was not that 
impressive. 
The following step of my investigation was an attempt to co-crystallize 
hormone melatonin aimed at improvement of its solubility in water. Despite 
the fact that a number of co-formers were used only three co-crystals of 
melatonin were obtained: two molecular and one ionic. The latter was 
obtained by the co-crystallization with calcium chloride and, in principle, it is of 
higher importance since it was obtained with the co-former that belongs to the 
GRAS list. The thermodynamic solubility measurements showed that ionic co-
crystal formation with CaCl2 significantly improved the solubility in water. 
 
4.3. The effect of co-crystallization on chirality and its possible 
application for chiral resolution. 
This part of the research combines the issue of chirality with that of ionic co-
crystal formation. Initially, we planned to investigate the influence of ICCs 
formation on the crystal structure of chiral molecules. To this end, both 
enantiopure and racemic amino acid histidine was co-crystallized with lithium 
and calcium halides.  The results of this research showed that the complexation 
of DL-histidine by lithium cations was enantioselective: the tetrahedral 
assembly around the cations favoured molecules of the same handedness. As a 
result, infinite enantiopure (L-His·Li)n
n+ / (D-His·Li)n
n+ chains are formed. 
Moreover, while the co-crystallization of DL-histidine with lithium chloride and 
bromide resulted into formation of the corresponding racemic ICCs, the 
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reaction lithium iodide proceeded a step further along the path towards chiral 
separation: spontaneous chiral resolution took place with the formation of 
conglomerate of D-His·LiI·H2O and L-His·LiI·H2O. In addition to this, it was 
established that the enantiopure chains observed in both racemic and 
conglomerate crystals were identical. 
The co-crystallization with calcium halides, in turn, did not show any effect on 
the chirality of the obtained ionic co-crystals. The interaction of both racemic 
and enantiopure histidine resulted into formation of the corresponding ionic 
co-crystals of the general formula (L-His)2∙CaX2∙nH2O (X= Cl and Br n=3, X= I 
n=4). The co-crystallization of the racemic histidine with calcium halides 
resulted into the corresponding racemic ICCs which accommodated molecules 
of both chiralities in the coordination sphere of the Ca2+ cations. 
Taking in consideration the information obtained by the co-crystallization 
histidine with lithium and calcium halides, it was speculated that the Li+ 
tetrahedral coordination could be the key factor in the lithium homochiral 
preference. To put this theory to test, it was decided to co-crystallize lithium 
halides with another amino acid – proline. It was also planned to investigate 
was the possible role of the anion in the chiral resolution since different results 
were obtained via co-crystallization of DL-histidine with LiCl, LiBr and LiI. The 
co-crystallization of both enantiopure and racemic proline with lithium halides 
showed similar behaviour to that previously observed in histidine ICCs. Once 
again in all the cases lithium showed a preference towards amino acids of the 
same chirality. However, this time we could observe conglomerate formation in 
the reactions of DL-proline with lithium chloride and bromide while the co-
crystallization with lithium iodide led to the formation of the racemic ICC. Later 
on, a racemate was also obtained with LiCl in one of the trials to recrystallize 
conglomerate D-Pro·LiCl·H2O and L-Pro·LiCl·H2O. These results allowed us to 
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exclude the role of the anion as a key factor in the spontaneous chiral 
resolution. Since the majority of ICCs were obtained in the form of hydrates, 
the thermal behaviour of the products and its impact on the chirality were also 
investigated. It was found that all the obtained ICCs could be dehydrated. The 
structure of the obtained ICCs was solved using XRPD data. The 
enantioselective complexation of proline by lithium cations was retained in the 
dehydration products. The dehydration of all ICCs was reversible: upon 
standing at open air the ICCs quickly rehydrated back. The dehydration process 
retained the racemate/conglomerate choice for the ICCs formed with lithium 
chloride and iodide, but swapped to the racemate structure when formed with 
lithium bromide. 
Taking into account the information of the co-crystallization results of amino 
acids histidine and proline with lithium and calcium halides it was speculated 
that the lithium homochiral preference could be caused by the tetrahedral 
geometry around lithium cations that could favour the coordination of 
molecules of the same chirality. To find it out an antiepileptic drug – 
levetiracetam and its racemic intermediate – RS-etiracetam were co-
crystallized with ZnCl2 since zinc is known to favour tetrahedral coordination. 
The complexation of RS-etiracetam to zinc cations was also enantioselective. In 
addition, it was possible to switch from a thermodynamically stable racemic 
compound to a thermodynamically stable conglomerate using different 
amounts of zinc chloride. 
In conclusion, I would like to say that the obtained results emphasized the fact 
that co-crystallization with metal ions favouring tetrahedral coordination could 
be successfully used to obtain chiral selectivity and conglomerate formation 
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